US20220119339A1 - Cationic pillararene compounds and compositions - Google Patents
Cationic pillararene compounds and compositions Download PDFInfo
- Publication number
- US20220119339A1 US20220119339A1 US17/452,970 US202117452970A US2022119339A1 US 20220119339 A1 US20220119339 A1 US 20220119339A1 US 202117452970 A US202117452970 A US 202117452970A US 2022119339 A1 US2022119339 A1 US 2022119339A1
- Authority
- US
- United States
- Prior art keywords
- independently
- compound
- group
- alkyl
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 150000001875 compounds Chemical class 0.000 title claims description 160
- 125000002091 cationic group Chemical group 0.000 title abstract description 33
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims abstract description 28
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 claims abstract description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 68
- -1 ammoniumoxy Chemical group 0.000 claims description 62
- 229910052736 halogen Inorganic materials 0.000 claims description 39
- 150000002367 halogens Chemical class 0.000 claims description 36
- 229910006069 SO3H Inorganic materials 0.000 claims description 34
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 150000001450 anions Chemical class 0.000 claims description 23
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 23
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 22
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- 125000005842 heteroatom Chemical group 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 150000001768 cations Chemical class 0.000 claims description 16
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 229920006395 saturated elastomer Polymers 0.000 claims description 11
- 125000006681 (C2-C10) alkylene group Chemical group 0.000 claims description 9
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 9
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 claims description 7
- 125000000909 amidinium group Chemical group 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-O hydrazinium(1+) Chemical compound [NH3+]N OAKJQQAXSVQMHS-UHFFFAOYSA-O 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 claims description 4
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 claims description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-O Pyrazolium Chemical compound C1=CN[NH+]=C1 WTKZEGDFNFYCGP-UHFFFAOYSA-O 0.000 claims description 4
- 125000004450 alkenylene group Chemical group 0.000 claims description 4
- 125000004419 alkynylene group Chemical group 0.000 claims description 4
- VUEDNLCYHKSELL-UHFFFAOYSA-N arsonium Chemical compound [AsH4+] VUEDNLCYHKSELL-UHFFFAOYSA-N 0.000 claims description 4
- YRPWLKVCRKAUAO-UHFFFAOYSA-N bismuthonium Chemical compound [BiH4+] YRPWLKVCRKAUAO-UHFFFAOYSA-N 0.000 claims description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 claims description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-O hydron;1,3-oxazole Chemical compound C1=COC=[NH+]1 ZCQWOFVYLHDMMC-UHFFFAOYSA-O 0.000 claims description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-O hydron;pyrimidine Chemical compound C1=CN=C[NH+]=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-O 0.000 claims description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-O hydron;quinoline Chemical compound [NH+]1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-O 0.000 claims description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-O isoquinolin-2-ium Chemical compound C1=[NH+]C=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-O 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims description 4
- SPVXKVOXSXTJOY-UHFFFAOYSA-O selenonium Chemical compound [SeH3+] SPVXKVOXSXTJOY-UHFFFAOYSA-O 0.000 claims description 4
- HISNRBVYBOVKMB-UHFFFAOYSA-N stibonium Chemical compound [SbH4+] HISNRBVYBOVKMB-UHFFFAOYSA-N 0.000 claims description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 claims description 4
- VTLHPSMQDDEFRU-UHFFFAOYSA-O telluronium Chemical compound [TeH3+] VTLHPSMQDDEFRU-UHFFFAOYSA-O 0.000 claims description 4
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims description 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 3
- 229910001914 chlorine tetroxide Inorganic materials 0.000 claims description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 3
- 230000032770 biofilm formation Effects 0.000 abstract description 62
- 150000004945 aromatic hydrocarbons Chemical class 0.000 abstract description 59
- 230000001580 bacterial effect Effects 0.000 abstract description 35
- 150000001492 aromatic hydrocarbon derivatives Chemical class 0.000 abstract description 25
- 230000002401 inhibitory effect Effects 0.000 abstract description 23
- 241001120493 Arene Species 0.000 abstract description 15
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 238000000354 decomposition reaction Methods 0.000 abstract description 4
- 239000003937 drug carrier Substances 0.000 abstract description 4
- 230000002538 fungal effect Effects 0.000 abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- 230000005764 inhibitory process Effects 0.000 description 35
- 230000000694 effects Effects 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- 238000000034 method Methods 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 239000007787 solid Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 25
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical group [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 23
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 22
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 18
- 229940125851 compound 27 Drugs 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 17
- 239000012736 aqueous medium Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 241000201788 Staphylococcus aureus subsp. aureus Species 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 13
- 241000943303 Enterococcus faecalis ATCC 29212 Species 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 125000002947 alkylene group Chemical group 0.000 description 11
- 230000003214 anti-biofilm Effects 0.000 description 11
- 229940126086 compound 21 Drugs 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000012300 argon atmosphere Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 239000002054 inoculum Substances 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 7
- 241000194032 Enterococcus faecalis Species 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 229940125846 compound 25 Drugs 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000001974 tryptic soy broth Substances 0.000 description 7
- 108010050327 trypticase-soy broth Proteins 0.000 description 7
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 244000000059 gram-positive pathogen Species 0.000 description 6
- 238000004896 high resolution mass spectrometry Methods 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 125000001453 quaternary ammonium group Chemical group 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 5
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 5
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 0 [1*]c1c([2*])c(O[5*][Y+])c(C)c([3*])c1O[4*][Y+].[CH3-].[CH3-] Chemical compound [1*]c1c([2*])c(O[5*][Y+])c(C)c([3*])c1O[4*][Y+].[CH3-].[CH3-] 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000003113 dilution method Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- DDFYFBUWEBINLX-UHFFFAOYSA-M tetramethylammonium bromide Chemical compound [Br-].C[N+](C)(C)C DDFYFBUWEBINLX-UHFFFAOYSA-M 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000003899 bactericide agent Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 229940127204 compound 29 Drugs 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 229940086542 triethylamine Drugs 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- 238000004679 31P NMR spectroscopy Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 241001240958 Pseudomonas aeruginosa PAO1 Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000194019 Streptococcus mutans Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WTPYFJNYAMXZJG-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)phenoxy]ethanol Chemical compound OCCOC1=CC=C(OCCO)C=C1 WTPYFJNYAMXZJG-UHFFFAOYSA-N 0.000 description 2
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003373 anti-fouling effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000006481 glucose medium Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002678 macrocyclic compounds Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 125000003367 polycyclic group Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RXJKFRMDXUJTEX-UHFFFAOYSA-N triethylphosphine Chemical compound CCP(CC)CC RXJKFRMDXUJTEX-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- WXYYACUWOMKZQC-UHFFFAOYSA-N 1-benzyl-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one Chemical compound C1=CC(C(C)C)=CC=C1C(C1=CC(OCC#C)=CC=C11)=NC(=O)N1CC1=CC=CC=C1 WXYYACUWOMKZQC-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 125000001627 3 membered heterocyclic group Chemical group 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- OLNDEKUAZANQDQ-UHFFFAOYSA-B BrB(Br)Br.CCOC(=O)CBr.CCc1cc(OC)c(Cc2cc(OC)c(Cc3cc(OC)c(Cc4cc(OC)c(Cc5cc(OC)c(C)cc5O)cc4O)cc3O)cc2O)cc1O.CCc1cc(OC)c(Cc2cc(OC)c(Cc3cc(OC)c(Cc4cc(OC)c(Cc5cc(OC)c(C)cc5OC)cc4OC)cc3OC)cc2OC)cc1OC.CCc1cc(OCC(=O)O)c(Cc2cc(OCC(=O)O)c(Cc3cc(OCC(=O)O)c(Cc4cc(OCC(=O)O)c(Cc5cc(OCC(=O)O)c(C)cc5OCC(=O)O)cc4OCC(=O)O)cc3OCC(=O)O)cc2OCC(=O)O)cc1OCC(=O)O.CCc1cc(OCC(=O)[O-])c(Cc2cc(OCC(=O)[O-])c(Cc3cc(OCC(=O)[O-])c(Cc4cc(OCC(=O)[O-])c(Cc5cc(OCC(=O)[O-])c(C)cc5OCC(=O)[O-])cc4OCC(=O)[O-])cc3OCC(=O)[O-])cc2OCC(=O)[O-])cc1OCC(=O)[O-].CCc1cc(OCC(C)=O)c(Cc2cc(OCC(C)=O)c(Cc3cc(OCC(C)=O)c(Cc4cc(OCC(C)=O)c(Cc5cc(OCC(C)=O)c(C)cc5OCC(C)=O)cc4OCC(C)=O)cc3OCC(C)=O)cc2OCC(C)=O)cc1OCC(C)=O.COc1ccc(OC)cc1.ClCCl.O.O=COO[K].O[Na].[KH].[Na+].[Na+] Chemical compound BrB(Br)Br.CCOC(=O)CBr.CCc1cc(OC)c(Cc2cc(OC)c(Cc3cc(OC)c(Cc4cc(OC)c(Cc5cc(OC)c(C)cc5O)cc4O)cc3O)cc2O)cc1O.CCc1cc(OC)c(Cc2cc(OC)c(Cc3cc(OC)c(Cc4cc(OC)c(Cc5cc(OC)c(C)cc5OC)cc4OC)cc3OC)cc2OC)cc1OC.CCc1cc(OCC(=O)O)c(Cc2cc(OCC(=O)O)c(Cc3cc(OCC(=O)O)c(Cc4cc(OCC(=O)O)c(Cc5cc(OCC(=O)O)c(C)cc5OCC(=O)O)cc4OCC(=O)O)cc3OCC(=O)O)cc2OCC(=O)O)cc1OCC(=O)O.CCc1cc(OCC(=O)[O-])c(Cc2cc(OCC(=O)[O-])c(Cc3cc(OCC(=O)[O-])c(Cc4cc(OCC(=O)[O-])c(Cc5cc(OCC(=O)[O-])c(C)cc5OCC(=O)[O-])cc4OCC(=O)[O-])cc3OCC(=O)[O-])cc2OCC(=O)[O-])cc1OCC(=O)[O-].CCc1cc(OCC(C)=O)c(Cc2cc(OCC(C)=O)c(Cc3cc(OCC(C)=O)c(Cc4cc(OCC(C)=O)c(Cc5cc(OCC(C)=O)c(C)cc5OCC(C)=O)cc4OCC(C)=O)cc3OCC(C)=O)cc2OCC(C)=O)cc1OCC(C)=O.COc1ccc(OC)cc1.ClCCl.O.O=COO[K].O[Na].[KH].[Na+].[Na+] OLNDEKUAZANQDQ-UHFFFAOYSA-B 0.000 description 1
- UKZUXPPGCYDAFS-UHFFFAOYSA-N BrCCOc1ccc(OCCBr)cc1.C.CCc1cc(OCCBr)c(Cc2cc(OCCBr)c(Cc3cc(OCCBr)c(Cc4cc(OCCBr)c(Cc5cc(OCCBr)c(Cc6cc(OCCBr)c(C)cc6OCCBr)cc5OCCBr)cc4OCCBr)cc3OCCBr)cc2OCCBr)cc1OCCBr.CCc1cc(OCC[N+](C)(C)C)c(Cc2cc(OCC[N+](C)(C)C)c(Cc3cc(OCC[N+](C)(C)C)c(Cc4cc(OCC[N+](C)(C)C)c(Cc5cc(OCC[N+](C)(C)C)c(Cc6cc(OCC[N+](C)(C)C)c(C)cc6OCC[N+](C)(C)C)cc5OCC[N+](C)(C)C)cc4OCC[N+](C)(C)C)cc3OCC[N+](C)(C)C)cc2OCC[N+](C)(C)C)cc1OCC[N+](C)(C)C.CN(C)C Chemical compound BrCCOc1ccc(OCCBr)cc1.C.CCc1cc(OCCBr)c(Cc2cc(OCCBr)c(Cc3cc(OCCBr)c(Cc4cc(OCCBr)c(Cc5cc(OCCBr)c(Cc6cc(OCCBr)c(C)cc6OCCBr)cc5OCCBr)cc4OCCBr)cc3OCCBr)cc2OCCBr)cc1OCCBr.CCc1cc(OCC[N+](C)(C)C)c(Cc2cc(OCC[N+](C)(C)C)c(Cc3cc(OCC[N+](C)(C)C)c(Cc4cc(OCC[N+](C)(C)C)c(Cc5cc(OCC[N+](C)(C)C)c(Cc6cc(OCC[N+](C)(C)C)c(C)cc6OCC[N+](C)(C)C)cc5OCC[N+](C)(C)C)cc4OCC[N+](C)(C)C)cc3OCC[N+](C)(C)C)cc2OCC[N+](C)(C)C)cc1OCC[N+](C)(C)C.CN(C)C UKZUXPPGCYDAFS-UHFFFAOYSA-N 0.000 description 1
- NDYGPVGYSXZCDZ-UHFFFAOYSA-N BrCCOc1ccc(OCCBr)cc1.CC#N.CCc1cc(OCCBr)c(Cc2cc(OCCBr)c(Cc3cc(OCCBr)c(Cc4cc(OCCBr)c(Cc5cc(OCCBr)c(C)cc5OCCBr)cc4OCCBr)cc3OCCBr)cc2OCCBr)cc1OCCBr.CCc1cc(OCC[N+](C)(C)C)c(Cc2cc(OCC[N+](C)(C)C)c(Cc3cc(OCC[N+](C)(C)C)c(Cc4cc(OCC[N+](C)(C)C)c(Cc5cc(OCC[N+](C)(C)C)c(C)cc5OCC[N+](C)(C)C)cc4OCC[N+](C)(C)C)cc3OCC[N+](C)(C)C)cc2OCC[N+](C)(C)C)cc1OCC[N+](C)(C)C.CCc1cc(OCC[n+]2ccn(C)c2)c(Cc2cc(OCC[n+]3ccn(C)c3)c(Cc3cc(OCC[n+]4ccn(C)c4)c(Cc4cc(OCC[n+]5ccn(C)c5)c(Cc5cc(OCC[n+]6ccn(C)c6)c(C)cc5OCC[n+]5ccn(C)c5)cc4OCC[n+]4ccn(C)c4)cc3OCC[n+]3ccn(C)c3)cc2OCC[n+]2ccn(C)c2)cc1OCC[n+]1ccn(C)c1.CN(C)C.OCCOc1ccc(OCCO)cc1 Chemical compound BrCCOc1ccc(OCCBr)cc1.CC#N.CCc1cc(OCCBr)c(Cc2cc(OCCBr)c(Cc3cc(OCCBr)c(Cc4cc(OCCBr)c(Cc5cc(OCCBr)c(C)cc5OCCBr)cc4OCCBr)cc3OCCBr)cc2OCCBr)cc1OCCBr.CCc1cc(OCC[N+](C)(C)C)c(Cc2cc(OCC[N+](C)(C)C)c(Cc3cc(OCC[N+](C)(C)C)c(Cc4cc(OCC[N+](C)(C)C)c(Cc5cc(OCC[N+](C)(C)C)c(C)cc5OCC[N+](C)(C)C)cc4OCC[N+](C)(C)C)cc3OCC[N+](C)(C)C)cc2OCC[N+](C)(C)C)cc1OCC[N+](C)(C)C.CCc1cc(OCC[n+]2ccn(C)c2)c(Cc2cc(OCC[n+]3ccn(C)c3)c(Cc3cc(OCC[n+]4ccn(C)c4)c(Cc4cc(OCC[n+]5ccn(C)c5)c(Cc5cc(OCC[n+]6ccn(C)c6)c(C)cc5OCC[n+]5ccn(C)c5)cc4OCC[n+]4ccn(C)c4)cc3OCC[n+]3ccn(C)c3)cc2OCC[n+]2ccn(C)c2)cc1OCC[n+]1ccn(C)c1.CN(C)C.OCCOc1ccc(OCCO)cc1 NDYGPVGYSXZCDZ-UHFFFAOYSA-N 0.000 description 1
- VZMVQECTUGWYDD-UHFFFAOYSA-N CC#N.CCc1cc(OCCCl)c(Cc2cc(OCCCl)c(Cc3cc(OCCCl)c(Cc4cc(OCCCl)c(Cc5cc(OCCCl)c(C)cc5OCCCl)cc4OCCCl)cc3OCCCl)cc2OCCCl)cc1OCCCl.CCc1cc(OCC[N+](C)(C)C)c(Cc2cc(OCC[N+](C)(C)C)c(Cc3cc(OCC[N+](C)(C)C)c(Cc4cc(OCC[N+](C)(C)C)c(Cc5cc(OCC[N+](C)(C)C)c(C)cc5OCC[N+](C)(C)C)cc4OCC[N+](C)(C)C)cc3OCC[N+](C)(C)C)cc2OCC[N+](C)(C)C)cc1OCC[N+](C)(C)C.CN(C)C.ClCCOc1ccc(OCCCl)cc1.OCCOc1ccc(OCCO)cc1 Chemical compound CC#N.CCc1cc(OCCCl)c(Cc2cc(OCCCl)c(Cc3cc(OCCCl)c(Cc4cc(OCCCl)c(Cc5cc(OCCCl)c(C)cc5OCCCl)cc4OCCCl)cc3OCCCl)cc2OCCCl)cc1OCCCl.CCc1cc(OCC[N+](C)(C)C)c(Cc2cc(OCC[N+](C)(C)C)c(Cc3cc(OCC[N+](C)(C)C)c(Cc4cc(OCC[N+](C)(C)C)c(Cc5cc(OCC[N+](C)(C)C)c(C)cc5OCC[N+](C)(C)C)cc4OCC[N+](C)(C)C)cc3OCC[N+](C)(C)C)cc2OCC[N+](C)(C)C)cc1OCC[N+](C)(C)C.CN(C)C.ClCCOc1ccc(OCCCl)cc1.OCCOc1ccc(OCCO)cc1 VZMVQECTUGWYDD-UHFFFAOYSA-N 0.000 description 1
- LMUUNMMNNLVMEZ-UHFFFAOYSA-N CCCCCCCCCCOc1cc(Cc2cc(OCC[N+](C)(C)C)c(Cc3cc(OCC[N+](C)(C)C)c(Cc4cc(OCC[N+](C)(C)C)c(Cc5cc(OCC[N+](C)(C)C)c(CC)cc5OCCCCCCCCCC)cc4OCCCCCCCCCC)cc3OCCCCCCCCCC)cc2OCCCCCCCCCC)c(OCC[N+](C)(C)C)cc1C.CCCCCCOc1cc(Cc2cc(OCC[N+](C)(C)C)c(Cc3cc(OCC[N+](C)(C)C)c(Cc4cc(OCC[N+](C)(C)C)c(Cc5cc(OCC[N+](C)(C)C)c(CC)cc5OCCCCCC)cc4OCCCCCC)cc3OCCCCCC)cc2OCCCCCC)c(OCC[N+](C)(C)C)cc1C.CCc1cc(OCC[n+]2ccn(C)c2)c(Cc2cc(OCC[n+]3ccn(C)c3)c(Cc3cc(OCC[n+]4ccn(C)c4)c(Cc4cc(OCC[n+]5ccn(C)c5)c(Cc5cc(OCC[n+]6ccn(C)c6)c(Cc6cc(OCC[n+]7ccn(C)c7)c(C)cc6OCC[n+]6ccn(C)c6)cc5OCC[n+]5ccn(C)c5)cc4OCC[n+]4ccn(C)c4)cc3OCC[n+]3ccn(C)c3)cc2OCC[n+]2ccn(C)c2)cc1OCC[n+]1ccn(C)c1 Chemical compound CCCCCCCCCCOc1cc(Cc2cc(OCC[N+](C)(C)C)c(Cc3cc(OCC[N+](C)(C)C)c(Cc4cc(OCC[N+](C)(C)C)c(Cc5cc(OCC[N+](C)(C)C)c(CC)cc5OCCCCCCCCCC)cc4OCCCCCCCCCC)cc3OCCCCCCCCCC)cc2OCCCCCCCCCC)c(OCC[N+](C)(C)C)cc1C.CCCCCCOc1cc(Cc2cc(OCC[N+](C)(C)C)c(Cc3cc(OCC[N+](C)(C)C)c(Cc4cc(OCC[N+](C)(C)C)c(Cc5cc(OCC[N+](C)(C)C)c(CC)cc5OCCCCCC)cc4OCCCCCC)cc3OCCCCCC)cc2OCCCCCC)c(OCC[N+](C)(C)C)cc1C.CCc1cc(OCC[n+]2ccn(C)c2)c(Cc2cc(OCC[n+]3ccn(C)c3)c(Cc3cc(OCC[n+]4ccn(C)c4)c(Cc4cc(OCC[n+]5ccn(C)c5)c(Cc5cc(OCC[n+]6ccn(C)c6)c(Cc6cc(OCC[n+]7ccn(C)c7)c(C)cc6OCC[n+]6ccn(C)c6)cc5OCC[n+]5ccn(C)c5)cc4OCC[n+]4ccn(C)c4)cc3OCC[n+]3ccn(C)c3)cc2OCC[n+]2ccn(C)c2)cc1OCC[n+]1ccn(C)c1 LMUUNMMNNLVMEZ-UHFFFAOYSA-N 0.000 description 1
- NPCWVSWCDSUFER-UHFFFAOYSA-N CCOc1cc(Cc2cc(OCCC[N+](C)(C)C)c(Cc3cc(OCCC[N+](C)(C)C)c(Cc4cc(OCCC[N+](C)(C)C)c(C)cc4OCC)cc3OCC)cc2OCC)c(OCCC[N+](C)(C)C)cc1Cc1cc(OCCCCCC[N+](C)(C)C)c(CC)cc1OCCCCCC[N+](C)(C)C.CCc1cc(OCCC[N+](C)(C)C)c(Cc2cc(OCCC[N+](C)(C)C)c(Cc3cc(OCCC[N+](C)(C)C)c(Cc4cc(OCCC[N+](C)(C)C)c(Cc5cc(OCCC[N+](C)(C)C)c(Cc6cc(OCCC[N+](C)(C)C)c(C)cc6OCCC[N+](C)(C)C)cc5OCCC[N+](C)(C)C)cc4OCCC[N+](C)(C)C)cc3OCCC[N+](C)(C)C)cc2OCCC[N+](C)(C)C)cc1OCCC[N+](C)(C)C.CCc1cc(OCCC[P+](CC)(CC)CC)c(Cc2cc(OCCC[P+](CC)(CC)CC)c(Cc3cc(OCCC[P+](CC)(CC)CC)c(Cc4cc(OCCC[P+](CC)(CC)CC)c(Cc5cc(OCCC[P+](CC)(CC)CC)c(C)cc5OCCC[P+](CC)(CC)CC)cc4OCCC[P+](CC)(CC)CC)cc3OCCC[P+](CC)(CC)CC)cc2OCCC[P+](CC)(CC)CC)cc1OCCC[P+](CC)(CC)CC.C[N+](C)(C)C.C[N+](C)(C)C.C[N+](C)(C)C.C[N+](C)(C)C Chemical compound CCOc1cc(Cc2cc(OCCC[N+](C)(C)C)c(Cc3cc(OCCC[N+](C)(C)C)c(Cc4cc(OCCC[N+](C)(C)C)c(C)cc4OCC)cc3OCC)cc2OCC)c(OCCC[N+](C)(C)C)cc1Cc1cc(OCCCCCC[N+](C)(C)C)c(CC)cc1OCCCCCC[N+](C)(C)C.CCc1cc(OCCC[N+](C)(C)C)c(Cc2cc(OCCC[N+](C)(C)C)c(Cc3cc(OCCC[N+](C)(C)C)c(Cc4cc(OCCC[N+](C)(C)C)c(Cc5cc(OCCC[N+](C)(C)C)c(Cc6cc(OCCC[N+](C)(C)C)c(C)cc6OCCC[N+](C)(C)C)cc5OCCC[N+](C)(C)C)cc4OCCC[N+](C)(C)C)cc3OCCC[N+](C)(C)C)cc2OCCC[N+](C)(C)C)cc1OCCC[N+](C)(C)C.CCc1cc(OCCC[P+](CC)(CC)CC)c(Cc2cc(OCCC[P+](CC)(CC)CC)c(Cc3cc(OCCC[P+](CC)(CC)CC)c(Cc4cc(OCCC[P+](CC)(CC)CC)c(Cc5cc(OCCC[P+](CC)(CC)CC)c(C)cc5OCCC[P+](CC)(CC)CC)cc4OCCC[P+](CC)(CC)CC)cc3OCCC[P+](CC)(CC)CC)cc2OCCC[P+](CC)(CC)CC)cc1OCCC[P+](CC)(CC)CC.C[N+](C)(C)C.C[N+](C)(C)C.C[N+](C)(C)C.C[N+](C)(C)C NPCWVSWCDSUFER-UHFFFAOYSA-N 0.000 description 1
- UYSYFNWACGJYSM-UHFFFAOYSA-N CCc1cc(OCC[N+](C)(C)C)c(Cc2cc(OCC[N+](C)(C)C)c(Cc3cc(OCC[N+](C)(C)C)c(Cc4cc(OCC[N+](C)(C)C)c(Cc5cc(OCC[N+](C)(C)C)c(C)cc5OCC[N+](C)(C)C)cc4OCC[N+](C)(C)C)cc3OCC[N+](C)(C)C)cc2OCC[N+](C)(C)C)cc1OCC[N+](C)(C)C.CCc1cc(OCC[N+](CC)(CC)CC)c(Cc2cc(OCC[N+](CC)(CC)CC)c(Cc3cc(OCC[N+](CC)(CC)CC)c(Cc4cc(OCC[N+](CC)(CC)CC)c(Cc5cc(OCC[N+](CC)(CC)CC)c(C)cc5OCC[N+](CC)(CC)CC)cc4OCC[N+](CC)(CC)CC)cc3OCC[N+](CC)(CC)CC)cc2OCC[N+](CC)(CC)CC)cc1OCC[N+](CC)(CC)CC.CCc1cc(OCC[n+]2ccn(C)c2)c(Cc2cc(OCC[n+]3ccn(C)c3)c(Cc3cc(OCC[n+]4ccn(C)c4)c(Cc4cc(OCC[n+]5ccn(C)c5)c(Cc5cc(OCC[n+]6ccn(C)c6)c(C)cc5OCC[n+]5ccn(C)c5)cc4OCC[n+]4ccn(C)c4)cc3OCC[n+]3ccn(C)c3)cc2OCC[n+]2ccn(C)c2)cc1OCC[n+]1ccn(C)c1 Chemical compound CCc1cc(OCC[N+](C)(C)C)c(Cc2cc(OCC[N+](C)(C)C)c(Cc3cc(OCC[N+](C)(C)C)c(Cc4cc(OCC[N+](C)(C)C)c(Cc5cc(OCC[N+](C)(C)C)c(C)cc5OCC[N+](C)(C)C)cc4OCC[N+](C)(C)C)cc3OCC[N+](C)(C)C)cc2OCC[N+](C)(C)C)cc1OCC[N+](C)(C)C.CCc1cc(OCC[N+](CC)(CC)CC)c(Cc2cc(OCC[N+](CC)(CC)CC)c(Cc3cc(OCC[N+](CC)(CC)CC)c(Cc4cc(OCC[N+](CC)(CC)CC)c(Cc5cc(OCC[N+](CC)(CC)CC)c(C)cc5OCC[N+](CC)(CC)CC)cc4OCC[N+](CC)(CC)CC)cc3OCC[N+](CC)(CC)CC)cc2OCC[N+](CC)(CC)CC)cc1OCC[N+](CC)(CC)CC.CCc1cc(OCC[n+]2ccn(C)c2)c(Cc2cc(OCC[n+]3ccn(C)c3)c(Cc3cc(OCC[n+]4ccn(C)c4)c(Cc4cc(OCC[n+]5ccn(C)c5)c(Cc5cc(OCC[n+]6ccn(C)c6)c(C)cc5OCC[n+]5ccn(C)c5)cc4OCC[n+]4ccn(C)c4)cc3OCC[n+]3ccn(C)c3)cc2OCC[n+]2ccn(C)c2)cc1OCC[n+]1ccn(C)c1 UYSYFNWACGJYSM-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000751137 Staphylococcus epidermidis RP62A Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229920002677 supramolecular polymer Polymers 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/50—Treatment of water, waste water, or sewage by addition or application of a germicide or by oligodynamic treatment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5407—Acyclic saturated phosphonium compounds
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
- C09D5/16—Antifouling paints; Underwater paints
- C09D5/1687—Use of special additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2303/00—Specific treatment goals
- C02F2303/20—Prevention of biofouling
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/92—Systems containing at least three condensed rings with a condensed ring system consisting of at least two mutually uncondensed aromatic ring systems, linked by an annular structure formed by carbon chains on non-adjacent positions of the aromatic system, e.g. cyclophanes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to cationic pillar[n]arenes, e.g., cationic pillar[ 5 - 6 ]arenes, and uses thereof in inhibiting or disrupting biofilm formation, or reducing biofilm.
- Bacterial biofilms are defined as microbial communities (cities of microbes) that are held together by an extracellular matrix.
- biofilms have an increasing interest in bacterial biofilms as a result of the fact that in the majority of the cases biofilms lead to a dramatic enhancement in resistance to antimicrobial agents (Fux et al., 2005; Davies, 2003; Rabin et al., 2015).
- planktonic bacteria bacteria that grow in suspension
- biofilm forming bacteria can be up to almost three orders of magnitude less susceptible to antibiotics (Bottcher et al., 2013).
- biofilms account for a large percentage of nosocomial and implanted device-derived microbial infections in patients (Davey and O'Toole, 2000).
- Biofilm matrices are composed of exo-polymeric substances (EPS) that are high-molecular weight compounds secreted by the bacteria into the extracellular environment and are crucial for the integrity of all biofilms (Bottcher et al., 2013; Davey and O'Toole, 2000).
- EPS components include polysaccharides also termed exo-polysaccharides, proteins, extracellular DNA, lipids and bacterial decomposition substances that are held together by a highly complex network of hydrogen bonds as well as ionic and van der Waals interactions between the different matrix components.
- the composition of biofilm matrices varies significantly amongst different bacterial strains; some matrices contain mainly exo-polysaccharides and some mainly proteins. Moreover, the structure of the proteins and the monosaccharide building blocks that compose exo-polysaccharides vary between different biofilm producing bacterial strains.
- biofilm forming bacterial cells leave the mature biofilm into the environment and remain as planktonic bacteria or establish new biofilm colonies depending on the environmental conditions.
- Clardy and coworkers previously reported a collection of synthetic guanidine- and bi-guanidine-based cationic amphiphiles that inhibited biofilm formation as well as eradicated existing biofilms of bacillus subtillis and Staphylococcus aureus strains (Bottcher et al., 2013). More recently, Wuest and coworkers reported a collection of quaternary ammonium amphiphiles (Jennings et al., 2014) that demonstrated antimicrobial activity against a collection of Gram positive and Gram negative bacterial strains.
- Pillar[n]arenes first reported in 2008 (Ogoshi et al., 2008), have symmetrical cylindrical structures and relatively large free volumes. Pillar[n]arenes can be obtained and functionalized by simple and high yield synthesis routes making them a versatile macrocycles for various applications. These macrocycles possess host-guest properties owing to their ⁇ -electron rich cavity and crown ether-like arrangement of oxygen atoms at both rims.
- pillar[n]arenes have been used in host-guest chemistry and as sensors and were used to construct supramolecular polymers, interlocked molecules, and hybrid biomolecular materials (Ogoshi et al., 2008; Ogoshi and Yamagishi, 2014; Cragg and Sharma, 2012; Xue et al., 2012; Dong et al., 2014a; Chunju, 2014; Ogoshi et al., 2016; Ma et al., 2016; Liz et al., 2016; Shi et al., 2016; Ogoshi et al., 2015; Nierengarten et al., 2013; Li, 2014; Yang et al., 2014; Adiri et al., 2013; Zhang and Zhao, 2013; Yao et al., 2014; Dong et al., 2014b; Mao et al., 2016; Wang et al., 2015; Jie et al., 2014).
- the present invention provides a compound of the formula I:
- the invention provides a compound of the formula I as defined above, wherein Y each independently is (i) a cation derived from a nitrogen-containing group and selected from an ammonium [—N + (R′) 3 ], hydrazinium [—N + (R′) 2 —N(R′) 2 ], ammoniumoxy [—N + (R′) 2 —O], iminium [—N + (R′) 2 ⁇ C ⁇ ], amidinium [—N + (R′) 2 —C(R′) ⁇ NR′], or guanidinium [—N + (R′) 2 —C( ⁇ NR′)—N(R′) 2 ]; (ii) a cation derived from a nitrogen-containing mono- or polycyclic heteroaromatic group and selected from pyrazolium, imidazolium, oxazolium, thiazolium, pyridinium, pyrimidinium, quinolinium, isoquinolinium, 1,2,4
- the present invention provides a composition
- a composition comprising a compound of the formula I as defined above, i.e., excluding the compounds excluded by the proviso above, and a carrier.
- the present invention relates to a method for inhibiting or disrupting biofilm formation in an aqueous media or on an object, or for reducing biofilm existing in an aqueous media or attached to an object, said method comprising contacting said aqueous media or object with a compound of the formula I, including the compounds excluded by the proviso above.
- the method of the present invention is for inhibiting or disrupting biofilm formation in an aqueous media, or for reducing biofilm existing in said aqueous media, and comprises in fact dissolving of said compound or a composition comprising it within said aqueous media.
- the method of the present invention is for inhibiting or disrupting biofilm formation on an object, or for reducing biofilm attached to said object, and comprises coating of said object with said compound or a composition comprising it, or immersing of said object within a composition comprising said compound, respectively.
- the present invention relates to a pharmaceutical composition for inhibiting or disrupting biofilm, e.g., bacterial or fungal biofilm, formation, or reducing biofilm, said composition comprising a pharmaceutically acceptable carrier, and a compound of the formula I wherein X is a pharmaceutically acceptable anion, including the compounds excluded by the proviso above.
- the present invention relates to a compound of the formula I, including the compounds excluded by the proviso above, for use in inhibiting or disrupting biofilm, e.g., bacterial or fungal biofilm, formation, or reducing biofilm.
- biofilm e.g., bacterial or fungal biofilm, formation, or reducing biofilm.
- the present invention relates to a method for inhibiting or disrupting biofilm formation, or reducing biofilm, in an individual in need thereof, comprising administering to said individual a therapeutically effective amount of a compound of the formula I, including the compounds excluded by the proviso above.
- FIG. 1 illustrates the stages of biofilm formation process.
- FIG. 2 shows inhibition of biofilm formation by pillar[ 6 ]arene 27 .
- Biofilms produced by S. aureus subsp. aureus Rosenbach ATCC 33592 (a) and by E. faecalis ATCC 29212 (b) in the presence of increasing concentrations of 27 were stained with crystal violet. Each concentration of compound was tested in five wells.
- FIGS. 4A-4C show the effect of initial inoculum on biofilm formation inhibition by compound 27.
- the compound was incubated with E. faecalis (ATCC 29212; right panels) and S. aureus subsp. aureus Rosenbach (ATCC 33592; left panels) at starter inoculums of OD 600 0.025 ( 4 A), 0.05 ( 4 B), or 0.10 ( 4 C).
- FIGS. 5A-5D show growth curves of bacteria in the presence of compound 27: ( 5 A) E. coli ATCC 25922, ( 5 B) P. aeruginosa PA01, ( 5 C) E. faecalis ATCC 29212, and ( 5 D) S. aureus subsp. aureus Rosenbach ATCC 33592. Bacteria were incubated with compound 27 (32 and 64 ⁇ g/mL) for 24 h at 37° C. Pillar[ 6 ]arene conjugate 27 did not inhibit the growth of these bacteria.
- FIGS. 6A-6B show the effect of compound 27 on the viability of IB3-1 cells ( 6 A); and THP-1 cells ( 6 B).
- FIG. 7 shows biofilms of S. aureus subsp. aureus Rosenbach ATCC 33592 in the presence of increasing concentrations ( ⁇ M) of pillar[ 5 ]arene derivatives (a) compound 29, (b) compound 30, (c) compound 25, and (d) compound 28 stained with crystal violet.
- FIG. 8 shows biofilms formed by E. faecalis ATCC 29212 in the presence of increasing concentrations ( ⁇ M) of pillar[ 5 ]arene derivatives (a) compound 29, (b) compound 30, (c) compound 25, and (d) compound 28 stained with crystal violet.
- FIG. 9 shows biofilms formed by S. aureus subsp. aureus Rosenbach ATCC 33592 in the presence of increasing concentrations of (a) compound 12 and (c) compound 11.
- FIGS. 11A-11B show 1 H NMR spectra of compound 28 after incubation pH (a) 7.4, (b) 2.3, and (c) 10.2 for 4 hours ( 11 A); and 1 H NMR spectra of compound 30 after incubation at pH (a) 7.4, (b) 2.3, and (c) 10.7 for 4 hours ( 11 B).
- FIGS. 12A-12B show biofilm formation by S. aureus subsp. aureus Rosenbach ATCC 33592 ( 12 A) and E. faecalis ATCC 29212 ( 12 B) in the presence of increasing concentrations ( ⁇ M) 28 and 30 that had been incubated for 4 hours at different pH levels.
- FIGS. 13A-13B show the cell toxicity of compounds 25, 29 and 30 on mammalian IB3-1 cell-line ( 13 A) and HaCaT cell-line ( 13 B).
- the present invention relates to cationic amphiphilic systems capable of interfering with the chemical interactions between different components of biofilm matrices, more particularly bacterial biofilm matrices, thereby inhibiting or preventing biofilm formation and facilitating existing biofilm decomposition without intervening with bacterial viability and damaging mammalian cell membranes as many families of cationic amphiphiles do.
- the invention provides cationic pillararene derivatives such as positively charged poly-ammonium, poly-phosphonium and poly-imidazolium pillararene derivatives.
- cationic pillararene derivatives such as positively charged poly-ammonium, poly-phosphonium and poly-imidazolium pillararene derivatives.
- These systems are water soluble organic salts containing both a lipophilic but relatively electron-rich cavity as well as two arrays of positively charged moieties of the two opposite faces of the pillararene backbone which can interact with the negatively charged membranes and other different molecular components of the biofilm matrices.
- novel cationic pillar[ 5 - 6 ]arene derivatives specifically disclosed herein are compounds of the formula I, wherein (i) n is 5; R 1 is —CH 2 —; R 2 and R 3 are H; R 4 and R 5 are —(CH 2 ) 3 —; and Y is —N + (CH 3 ) 3 or —P + (CH 3 ) 3 , herein identified compound 25 and 29, respectively; (ii) n is 5; R 1 is —CH 2 —; R 2 and R 3 are H; R 4 and R 5 are —(CH 2 ) 3 —; and Y is —N + (C 2 H 5 ) 3 or —P + (C 2 H 5 ) 3 , herein identified compound 28 and 30, respectively; (iii) n is 5; R 1 is —CH 2 —; R 2 and R 3 are H; R 4 and R 5 are —(CH 2 ) 6 —, and Y is —N + (CH 3 ) 3
- Additional cationic pillar[ 5 - 6 ]arene derivatives specifically exemplified are compounds of the formula I, wherein (i) n is 5; R 1 is —CH 2 —; R 2 and R 3 are H; R 4 and R 5 are —(CH 2 ) 2 —; and Y is —N + (CH 3 ) 3 , —N + (C 2 H 5 ) 3 , or 1-methyl-imidazolium-3-yl, herein identified compound 21 (or 26), 23 and 22, respectively; or (ii) n is 6; R 1 is —CH 2 —; R 2 and R 3 are H; R 4 and R 5 are —(CH 2 ) 2 —, and Y is —N + (CH 3 ) 3 , or 1-methyl-imidazolium-3-yl, herein identified compound 27 and 33, respectively.
- X is Br ⁇ or Cl ⁇ .
- the water soluble cationic pillar[ 5 - 6 ]arene derivatives tested are extremely efficient in inhibiting biofilm formation at sub ⁇ M concentrations, without affecting the tested bacterial cell viability or causing measurable damage to the membranes of mammalian red blood cells (RBCs).
- the phosphonium-decorated pillararenes exhibited similar potencies as inhibitors of biofilm formation as their corresponding ammonium analogues, demonstrating that the number of positively charged groups and not their chemical identity are key to their anti-biofilm activity.
- the pillararene platform appears to be important and positive charges operating cooperatively are needed for effective anti-biofilm activity, as indicated by our finding that the respective cationic monomers were completely inactive.
- the cationic pillararene derivatives tested retained their anti-biofilm capability even after four hours of exposure to acidic or alkaline pH.
- the organisms in which the compounds were found to inhibit biofilm formation include clinical pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa and more.
- Such cationic pillararene derivatives can thus be used to fight biofilm formation and to eradicate existing biofilms in myriad of applications such as in water reservoirs, closed circuit water systems, in painting industries especially in dyes used to protect vessels from water, in toothpaste and dentistry industry, and more.
- the compounds may also be used to fight biofilm on surfaces in hospitals, medical devices and implants, as well as in external and internal pads and optionally in conjunction with antibiotic treatments.
- the present invention thus provides a compound of the formula I:
- halogen refers to a halogen and includes fluoro, chloro, bromo, and iodo, and it is preferably chloro or bromo.
- alkyl typically means a linear or branched saturated hydrocarbon radical having 1-8 carbon atoms and includes, e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isoamyl, 2,2-dimethylpropyl, n-hexyl, n-heptyl, n-octyl, and the like.
- Preferred are (C 1 -C 6 )alkyl groups, more preferably (C 1 -C 4 )alkyl groups, most preferably methyl, ethyl or propyl.
- the alkyl defined herein may optionally be substituted with one or more groups each independently selected from halogen, —COR, —COOR, —OCOOR, —OCON(R) 2 , —CN, —NO 2 , —SR, —OR, —N(R) 2 , —CON(R) 2 , —SO 2 R, —SO 3 R or —S( ⁇ O)R, wherein R is H or unsubstituted (C 1 -C 5 )alkyl.
- alkylene typically means a straight or branched divalent hydrocarbon radical having 1-10 carbon atoms, e.g., methylene, ethylene, propylene, butylene, 2-methylpropylene, pentylene, 2-methylbutylene, hexylene, 2-methylpentylene, 3-methylpentylene, 2,3-dimethylbutylene, heptylene, octylene, nonylene, decanylene, and the like.
- Preferred are (C 1 -C 8 )alkylene or (C 1 -C 6 )alkylene, more preferably (C 1 -C 4 )alkylene, most preferably methylene, ethylene, propylene, or butylene.
- alkenylene and alkynylene typically mean straight or branched divalent hydrocarbon radicals having 2-10 carbon atoms, and one or more double or triple bonds, respectively.
- aryl denotes an aromatic carbocyclic group having 6-10 carbon atoms consisting of a single ring or condensed multiple rings such as, but not limited to, phenyl and naphthyl.
- the aryl defined herein may optionally be substituted with one or more groups each independently selected from halogen, —COR, —COOR, —OCOOR, —OCON(R) 2 , —CN, —NO 2 , —SR, —OR, —N(R) 2 , —CON(R) 2 , —SO 2 R, —SO 3 R, —S( ⁇ O)R, or —(C 1 -C 5 )alkyl, wherein R is H or unsubstituted (C 1 -C 5 )alkyl.
- arylenediyl refers to a divalent radical derived from an “aryl” as defined herein by removal of a further hydrogen atom from any of the ring atoms.
- heterocyclic ring denotes a mono- or poly-cyclic non-aromatic ring of 4-12 atoms containing at least one carbon atom and one to three heteroatoms selected from sulfur, oxygen or nitrogen, which may be saturated or unsaturated, i.e., containing at least one unsaturated bond. Preferred are 3- or 7-membered heterocyclic rings.
- heterocyclyl refers to any univalent radical derived from a heterocyclic ring as defined herein by removal of hydrogen from any ring atom. Examples of such radicals include, without limitation, piperidino, 4-morpholinyl, or pyrrolidinyl.
- the heterocyclyl defined herein may optionally be substituted, at any position of the ring, with one or more groups each independently selected from halogen, —COR, —COOR, —OCOOR, —OCON(R) 2 , —CN, —NO 2 , —SR, —OR, —N(R) 2 , —CON(R) 2 , —SO 2 R, —SO 3 R, —S( ⁇ O)R, or —(C 1 -C 5 )alkyl, wherein R is H or unsubstituted (C 1 -C 5 )alkyl.
- heteroaryl refers to a radical derived from a 5-10-membered mono- or poly-cyclic heteroaromatic ring containing 1-3, preferably 1-2, heteroatoms selected from nitrogen, sulfur or oxygen.
- mono-cyclic heteroaryls include, without being limited to, pyrrolyl, furyl, thienyl, thiazinyl, pyrazolyl, pyrazinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, 1,2,3-triazinyl, 1,3,4-triazinyl, and 1,3,5-triazinyl.
- Polycyclic heteroaryl radicals are preferably composed of two rings such as, but not limited to, benzofuryl, isobenzofuryl, benzothienyl, indolyl, quinolinyl, isoquinolinyl, imidazo[1,2-a]pyridyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, pyrido[1,2-a]pyrimidinyl and 1,3-benzodioxinyl.
- the heteroaryl may optionally be substituted by one or more groups each independently selected from halogen, —COR, —COOR, —OCOOR, —OCON(R) 2 , —CN, —NO 2 , —SR, —OR, —N(R) 2 , —CON(R) 2 , —SO 2 R, —SO 3 R, —S( ⁇ O)R, or —(C 1 -C 5 )alkyl, wherein R is H or unsubstituted (C 1 -C 5 )alkyl. It is to be understood that when a polycyclic heteroaryl is substituted, the substitution may be in any of the carbocyclic and/or heterocyclic rings.
- heteroarylenediyl denotes a divalent radical derived from a “heteroaryl” as defined herein by removal of a further hydrogen atom from any of the ring atoms.
- cation derived from a nitrogen-containing group denotes for example, but without limiting to, an ammonium [—N + (R′) 3 ], hydrazinium [—N + (R′) 2 —N(R′) 2 ], ammoniumoxy [—N + (R′) 2 ⁇ O], iminium [—N + (R′) 2 ⁇ C ⁇ ], amidinium [—N + (R′) 2 —C(R′) ⁇ NR′], or guanidinium [—N + (R′) 2 —C( ⁇ NR′)—N(R′) 2 ], wherein R′ each independently is H, (C 1 -C 6 )alkyl, phenyl, benzyl, or heterocyclyl, or two R's together with the N atom to which they are attached form a 3-7 membered saturated ring, optionally containing one or more heteroatoms selected from O, S or N and optionally further substituted at the additional N atom.
- cation derived from a nitrogen-containing mono- or polycyclic heteroaromatic group optionally containing O, S or additional N atoms denotes for example, but without limiting to, pyrazolium, imidazolium, oxazolium, thiazolium, pyridinium, pyrimidinium, quinolinium, isoquinolinium, 1,2,4-triazinium, 1,3,5-triazinium, or purinium, optionally substituted by one or more groups each independently selected from halogen, (C 1 -C 6 )alkyl, —COH, —COOH, —OCOOH, —OCONH 2 , —CN, —NO 2 , —SH, —OH, —NH 2 , —CONH 2 , —SO 3 H, —SO 2 H, or —S( ⁇ O)H;
- cation derived from an onium group not containing nitrogen denotes for example, but without limiting, phosphonium [—P + (R′) 3 ], arsonium [—As + (R′) 3 ], oxonium [—O + (R′) 2 ], sulfonium [—S + (R′) 2 ], selenonium [—Se + (R′) 2 ], telluronium [—Te + (R′) 2 ], stibonium [—Sb + (R′) 3 ], or bismuthonium [—Bi + (R′) 3 ], wherein R′ each independently is H, (C 1 -C 6 )alkyl, phenyl, benzyl, or heterocyclyl.
- the cation derived from an onium group not containing nitrogen is a phosphonium as defined hereinabove.
- the compound of the present invention is a compound of the formula I, wherein R 1 is —CR 6 R 7 —, wherein R 6 and R 7 each independently is H, halogen, —COH, —COOH, —OCOOH, —OCONH 2 , —CN, —NO 2 , —SH, —OH, —NH 2 , —CONH 2 , —SO 3 H, —SO 2 H, —S( ⁇ O)H, or (C 1 -C 5 )alkyl optionally substituted by one or more groups each independently selected from —COH, —COOH, —OCOOH, —OCONH 2 , —CN, —NO 2 , —SH, —OH, —NH 2 , —CONH 2 , —SO 3 H, —SO 2 H, —S( ⁇ O)H, —N + (R′) 3 or —P + (R′) 3 , wherein R′ each independently is H,
- R 6 and R 7 each independently is (C 1 -C 5 )alkyl, preferably (C 1 -C 4 )alkyl, or H.
- R 1 is —CH 2 —, i.e., R 6 and R 7 are each H.
- the compound of the present invention is a compound of the formula I, wherein R 2 and R 3 each independently is H, or (C 1 -C 4 )alkyl, preferably (C 1 -C 2 )alkyl, optionally substituted by one or more groups each independently selected from halogen, —COH, —COOH, —OCOOH, —OCONH 2 , —CN, —NO 2 , —SH, —OH, —NH 2 , —CONH 2 , —SO 3 H, —SO 2 H, —S( ⁇ O)H, —N + (R′) 3 or —P + (R′) 3 , wherein R′ each independently is H, (C 1 -C 4 )alkyl, phenyl, or benzyl. Particular such compounds are those wherein R 2 and R 3 each independently is (C 1 -C 4 )alkyl, preferably (C 1 -C 2 )alkyl, or H.
- the compound of the present invention is a compound of the formula I, wherein R 4 and R 5 each independently is (C 2 -C 10 )alkylene optionally substituted and further optionally interrupted as defined above.
- R 4 and R 5 each independently is (C 2 -C 10 )alkylene, (C 2 -C 8 )alkylene or (C 2 -C 6 )alkylene, optionally substituted by one or more groups each independently selected from halogen, —COH, —COOH, —OCOOH, —OCONH 2 , —CN, —NO 2 , —SH, —OH, —NH 2 , —CONH 2 , —SO 3 H, —SO 2 H, —S( ⁇ O)H, (C 6 )aryl, (C 1 -C 4 )alkylene-(C 6 )aryl, heteroaryl, or (C 1 -C 4 )alkylene-heteroaryl, and
- R 4 and R 5 each independently is (C 2 -C 10 )alkylene, (C 2 -C 8 )alkylene or (C 2 -C 6 )alkylene, optionally interrupted by one or more identical or different heteroatoms, preferably one or more O atoms.
- the compound of the present invention is a compound of the formula I, wherein R 4 and R 5 are identical.
- the compound of the present invention is a compound of the formula I, wherein Y each independently is (i) ammonium [—N + (R′) 3 ] or phosphonium [—P + (R′) 3 ], wherein R′ each independently is H, (C 1 -C 6 )alkyl, phenyl, benzyl, or heterocyclyl; or (ii) imidazolium, optionally substituted by one or more groups each independently selected from halogen, (C 1 -C 6 )alkyl, —COH, —COOH, —OCOOH, —OCONH 2 , —CN, —NO 2 , —SH, —OH, —NH 2 , —CONH 2 , —SO 3 H, —SO 2 H, or —S( ⁇ O)H.
- Y each independently is (i) ammonium [—N + (R′) 3 ] or phosphonium [—P + (R′) 3 ], wherein R
- Y each independently is ammonium [—N + (R′) 3 ] or phosphonium [—P + (R′) 3 ], wherein R′ each independently is H, methyl, ethyl, or propyl; or 1-methyl-imidazolium-3-yl.
- the compound of the present invention is a compound of the formula I, wherein n is an integer of 5, 6, 7 or 8, preferably 5 or 6.
- the compound of the present invention is a compound of the formula I, wherein (i) R 1 is —CR 6 R 7 —, wherein R 6 and R 7 each independently is H, halogen, —COH, —COOH, —OCOOH, —OCONH 2 , —CN, —NO 2 , —SH, —OH, —NH 2 , —CONH 2 , —SO 3 H, —SO 2 H, —S( ⁇ O)H, or (C 1 -C 5 )alkyl optionally substituted by one or more groups each independently selected from —COH, —COOH, —OCOOH, —OCONH 2 , —CN, —NO 2 , —SH, —OH, —NH 2 , —CONH 2 , —SO 3 H, —SO 2 H, —S( ⁇ O)H, —N + (R′) 3 or —P + (R′) 3 , wherein R
- the compound of the invention is a compound of the formula I, wherein R 1 is —CH 2 —; R 2 and R 3 are H; and R 4 and R 5 each independently is (C 2 -C 10 )alkylene, (C 2 -C 8 )alkylene or (C 2 -C 6 )alkylene, optionally interrupted by one or more 0 atoms.
- Y each independently is (i) ammonium [—N + (R′) 3 ] or phosphonium [—P + (R′) 3 ], wherein R′ each independently is H, (C 1 -C 6 )alkyl, phenyl, benzyl, or heterocyclyl, but preferably H, methyl, ethyl or propyl; or (ii) imidazolium, optionally substituted by one or more groups each independently selected from halogen, (C 1 -C 6 )alkyl, —COH, —COOH, —OCOOH, —OCONH 2 , —CN, —NO 2 , —SH, —OH, —NH 2 , —CONH 2 , —SO 3 H, —SO 2 H, or —S( ⁇ O)H, but preferably 1-methyl-imidazolium-3-yl.
- n is an integer of 5 or 6.
- Specific cationic pillararenes are the compounds of the formula I, wherein R 1 is —CH 2 —; R 2 and R 3 are H; X is a counter anion as defined above; and: (i) R 4 and R 5 are —(CH 2 ) 3 —, or —(CH 2 ) 6 —; Y is —N + (CH 3 ) 3 , —N + (C 2 H 5 ) 3 , —P + (CH 3 ) 3 , or —P + (C 2 H 5 ) 3 ; and n is 5; or (ii) R 4 and R 5 are —(CH 2 ) 3 —; Y is —N + (CH 3 ) 3 , —P + (CH 3 ) 3 , or 1-methyl-imidazolium-3-yl; and n is 6.
- the cationic pillararenes of the invention also referred to herein as “biofilm inhibitors”, can be prepared by any suitable procedure and technology known in the art, e.g., as exemplified herein and depicted in detail in Schemes 1-3.
- the present invention provides a composition comprising a carrier and a compound of the formula I as defined in any one of the embodiments above, but excluding the compounds wherein R 1 is —CH 2 —; R 2 and R 3 are H; and: (i) n is 5; R 4 and R 5 are —(CH 2 ) 2 —; and Y is 1-methyl-imidazolium-3-yl or —N + (CH 3 ) 3 ; (ii) n is 5; R 4 and R 5 are —(CH 2 ) 3 —; and Y is —P + (C 4 H 9 ) 3 ; (iii) n is 5; R 4 and R 5 are —(CH 2 ) 4 —; and Y is —N + (CH 3 ) 3 ; (iv) n is 6; R 4 and R 5 are —(CH 2 ) 2 —; and Y is —N + (CH 3 ) 3 ; (v) n is 6; R 4 and R 5
- the composition of the present invention comprises a compound selected from those specifically disclosed herein, i.e., a compound of the formula I, wherein R 1 is —CH 2 —; R 2 and R 3 are H; X is a counter anion as defined above; and: (i) R 4 and R 5 are —(CH 2 ) 3 —, or —(CH 2 ) 6 —; Y is —N + (CH 3 ) 3 , —N + (C 2 H 5 ) 3 , —P + (CH 3 ) 3 , or —P + (C 2 H 5 ) 3 ; and n is 5; or (ii) R 4 and R 5 are —(CH 2 ) 3 —; Y is —N + (CH 3 ) 3 , —P + (CH 3 ) 3 , or 1-methyl-imidazolium-3-yl; and n is 6.
- the present invention relates to a method for inhibiting or disrupting biofilm formation in an aqueous media or on an object, or for reducing biofilm existing in an aqueous media or attached to an object, said method comprising contacting said aqueous media or object with a compound of the formula I as defined in any one of the embodiments above, including the compounds wherein R 1 is —CH 2 —; R 2 and R 3 are H; and: (i) n is 5; R 4 and R 5 are —(CH 2 ) 2 —; and Y is 1-methyl-imidazolium-3-yl or —N + (CH 3 ) 3 ; (ii) n is 5; R 4 and R 5 are —(CH 2 ) 3 —; and Y is —P + (C 4 H 9 ) 3 ; (iii) n is 5; R 4 and R 5 are —(CH 2 ) 4 —; and Y is —N + (CH 3 ) 3 ;
- the method of the present invention comprises contacting said aqueous media or object with a compound of the formula I, wherein R 1 is —CH 2 —; R 2 and R 3 are H; R 4 and R 5 are identical and each one is —(CH 2 ) 2-10 —, i.e., —(CH 2 ) 2 , —(CH 2 ) 3 , —(CH 2 ) 4 , —(CH 2 ) 5 , —(CH 2 ) 6 , —(CH 2 ) 7 , —(CH 2 ) 8 , —(CH 2 ) 9 , or —(CH 2 ) 10 ; Y is —N + (CH 3 ) 3 , —N + (C 2 H 5 ) 3 , —P + (CH 3 ) 3 , —P + (C 2 H 5 ) 3 , or 1-methyl-imidazolium-3-yl; n is 5 or 6; and X is a counter ani
- the method of the present invention is for inhibiting or disrupting biofilm formation in an aqueous media, i.e., a medium having water in it, or for reducing biofilm existing in said aqueous media, wherein said contacting comprises dissolving a compound of the formula I, or a composition comprising it, within said aqueous media.
- the method of the present invention is for inhibiting or disrupting biofilm formation on an object, or for reducing biofilm attached to said object, wherein said contacting comprises coating said object with a compound of the formula I, or a composition comprising it, or immersing said object within a composition comprising said compound, respectively.
- the object being “treated” according to the method of the present invention may be, without being limited to, an object designed for functioning in water, e.g., the hull of a boat, a pipe, a filter, a pump, or a heat-exchanger; a medical implant such as a stent; a medical device such as a catheter; or a biomedical pad such as an adhesive bandage.
- the method of the present invention comprises coating said object with a composition comprising a compound of the formula I, i.e., with an antifouling composition such as antifouling paints and coatings for use inter alia in the food industry and hospitals.
- a composition comprising a compound of the formula I, i.e., with an antifouling composition
- an antifouling composition such as antifouling paints and coatings for use inter alia in the food industry and hospitals.
- paints and coatings may be formulated, e.g., as sprays or hydrogels.
- the method of the present invention results in increased sensitivity of said aqueous media or object to a bacteriocide, i.e., a substance that kills bacteria such as a disinfectant (an antimicrobial agent that is applied to non-living objects to destroy microorganisms that are living on the objects), antiseptic, or antibiotic, and optionally further comprises contacting said aqueous media or object with said bacteriocide.
- a bacteriocide i.e., a substance that kills bacteria such as a disinfectant (an antimicrobial agent that is applied to non-living objects to destroy microorganisms that are living on the objects), antiseptic, or antibiotic
- the aqueous media or object “treated” by the method of the invention can be contacted with said compound of the formula I and said bacteriocide either at the same time (i.e., contacted with a combination of said compound of the formula I and said bacteriocide) or sequentially at any order.
- the present invention relates to a pharmaceutical composition for inhibiting or disrupting biofilm, e.g., bacterial or fungal biofilm, formation, or reducing biofilm, said composition comprising a pharmaceutically acceptable carrier, and a compound of the formula I as defined in any one of the embodiments above, including the compounds wherein R 1 is —CH 2 —, R 2 and R 3 are H; and: (i) n is 5; R 4 and R 8 are —(CH 2 ) 2 —; and Y is 1-methyl-imidazolium-3-yl or —N + (CH 3 ) 3 ; (ii) n is 5; R 4 and R 5 are —(CH 2 ) 3 —; and Y is —P + (C 4 H 9 ) 3 ; (iii) n is 5; R 4 and R 5 are —(CH 2 ) 4 —; and Y is —N + (CH 3 ) 3 ; (iv) n is 6; R 4 and R and R
- Pharmaceutically acceptable anions include, without limiting, chloride, bromide, iodide, acetate, mesylate, esylate, maleate, fumarate, tartrate, bitartrate, sulfate, p-toluenesulfonate, benzenesulfonate, methanesulfonate, ethanedisulfonate (edisylate), ethanesulfonate (esylate), tosylate, benzoate, acetate, phosphate, carbonate, bicarbonate, succinate, and citrate. Multiple anions can be used in a single preparation if desired.
- the pharmaceutical composition of the present invention comprises a compound of the formula I, wherein R 1 is —CH 2 —; R 2 and R 3 are H; R 4 and R 8 are identical and each one is —(CH 2 ) 2-10 —, i.e., —(CH 2 ) 2 , —(CH 2 ) 3 , —(CH 2 ) 4 , —(CH 2 ) 5 , —(CH 2 ) 6 , —(CH 2 ) 7 , —(CH 2 ) 8 , —(CH 2 ) 9 , or —(CH 2 ) 10 ; Y is —N + (CH 3 ) 3 , —N + (C 2 H 5 ) 3 , —P + (CH 3 ) 3 , —P + (C 2 H 5 ) 3 , or 1-methyl-imidazolium-3-yl; n is 5 or 6; and X is a pharmaceutically acceptable anion, wherein each one of the
- compositions provided by the present invention may be prepared by conventional techniques, e.g., as described in Remington: The Science and Practice of Pharmacy, 19 th Ed., 1995.
- the compositions can be prepared, e.g., by uniformly and intimately bringing the active agent, i.e., the compound of the formula I, into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired formulation.
- the compositions may be in liquid, solid or semisolid form and may further include pharmaceutically acceptable fillers, carriers, diluents or adjuvants, and other inert ingredients and excipients.
- the pharmaceutical composition of the present invention is formulated as nanoparticles.
- compositions can be formulated for any suitable route of administration, e.g., for parenteral administration such as intravenous, intraarterial, intrathecal, intrapleural, intratracheal, intraperitoneal, intramuscular or subcutaneous administration, topical administration, oral or enteral administration, or for inhalation. In certain embodiments, these compositions are formulated for either topical administration or for inhalation.
- parenteral administration such as intravenous, intraarterial, intrathecal, intrapleural, intratracheal, intraperitoneal, intramuscular or subcutaneous administration, topical administration, oral or enteral administration, or for inhalation.
- these compositions are formulated for either topical administration or for inhalation.
- the pharmaceutical composition of the invention may be in the form of a sterile injectable aqueous or oleaginous suspension, which may be formulated according to the known art using suitable dispersing, wetting or suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent.
- Acceptable vehicles and solvents include, without limiting, water, Ringer's solution and isotonic sodium chloride solution.
- compositions for topical administration may thus be in the form of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve, an ointment, a serum, an anhydrous stick, oil based sprays, oil-in-water emulsions or water-in-oil emulsions.
- the pharmaceutical composition of the invention is a dental composition formulated, e.g., as a mouthwash, toothpaste, a composition for root canal cleaning and disinfection, or a filling composition with biofilm inhibition/prevention properties.
- the pharmaceutical composition of the invention is formulated for hygienic wash.
- compositions according to the present invention when formulated for inhalation, may be administered utilizing any suitable device known in the art, such as metered dose inhalers, liquid nebulizers, dry powder inhalers, sprayers, thermal vaporizers, electrohydrodynamic aerosolizers, and the like.
- compositions according to the present invention when formulated for administration route other than parenteral administration, may be in a form suitable for oral use, e.g., as tablets, troches, lozenges, aqueous, or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
- Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and may further comprise one or more agents selected from sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
- Tablets contain the active agent(s) in admixture with non-toxic pharmaceutically acceptable excipients, which are suitable for the manufacture of tablets.
- excipients may be, e.g., inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating and disintegrating agents, e.g., corn starch or alginic acid; binding agents, e.g., starch, gelatin or acacia; and lubricating agents, e.g., magnesium stearate, stearic acid, or talc.
- inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate
- granulating and disintegrating agents e.g., corn starch or alginic acid
- binding agents e.g., starch, gelatin or acacia
- lubricating agents e.g.,
- the tablets may be either uncoated or coated utilizing known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated using the techniques described in the U.S. Pat. Nos. 4,256,108, 4,166,452 and 4,265,874 to form osmotic therapeutic tablets for control release.
- the pharmaceutical composition of the invention may also be in the form of oil-in-water emulsion.
- compositions of the invention may be formulated for controlled release of the active agent.
- Such compositions may be formulated as controlled-release matrix, e.g., as controlled-release matrix tablets in which the release of a soluble active agent is controlled by having the active diffuse through a gel formed after the swelling of a hydrophilic polymer brought into contact with dissolving liquid (in vitro) or gastro-intestinal fluid (in vivo).
- Many polymers have been described as capable of forming such gel, e.g., derivatives of cellulose, in particular the cellulose ethers such as hydroxypropyl cellulose, hydroxymethyl cellulose, methylcellulose or methyl hydroxypropyl cellulose, and among the different commercial grades of these ethers are those showing fairly high viscosity.
- compositions comprise the active agent formulated for controlled release in microencapsulated dosage form, in which small droplets of the active agent are surrounded by a coating or a membrane to form particles in the range of a few micrometers to a few millimeters.
- biodegradable polymers wherein as the polymer degrades, the active agent is slowly released.
- the most common class of biodegradable polymers is the hydrolytically labile polyesters prepared from lactic acid, glycolic acid, or combinations of these two molecules.
- Polymers prepared from these individual monomers include poly (D,L-lactide) (PLA), poly (glycolide) (PGA), and the copolymer poly (D,L-lactide-co-glycolide) (PLG).
- compositions of the invention can be provided in a variety of dosages, wherein the actual dose administered will depend on the state of the individual treated, and will be determined as deemed appropriate by the practitioner.
- the present invention relates to a compound of the formula I as defined in any one of the embodiments above, including the compounds wherein R 1 is —CH 2 —; R 2 and R 3 are H; and: (i) n is 5; R 4 and R 5 are —(CH 2 ) 2 —; and Y is 1-methyl-imidazolium-3-yl or —N + (CH 3 ) 3 ; (ii) n is 5; R 4 and R 5 are —(CH 2 ) 3 —; and Y is —P + (C 4 H 9 ) 3 ; (iii) n is 5; R 4 and R 5 are —(CH 2 ) 4 —; and Y is —N + (CH 3 ) 3 ; (iv) n is 6; R 4 and R 5 are —(CH 2 ) 2 —; and Y is —N + (CH 3 ) 3 ; (v) n is 6; R 4 and R 5 are —(CH 2 ) 2
- the compound used for inhibiting or disrupting biofilm formation, or for reducing biofilm is a compound of the formula I, wherein R 1 is —CH 2 —; R 2 and R 3 are H; R 4 and R 5 are identical and each one is —(CH 2 ) 2-10 —, i.e., —(CH 2 ) 2 , —(CH 2 ) 3 , —(CH 2 ) 4 , —(CH 2 ) 5 , —(CH 2 ) 6 , —(CH 2 ) 7 , —(CH 2 ) 8 , —(CH 2 ) 9 , or —(CH 2 ) 10 ; Y is —N + (CH 3 ) 3 , —N + (C 2 H 5 ) 3 , —P + (CH 3 ) 3 , —P + (C 2 H 5 ) 3 , or 1-methyl-imidazolium-3-yl; n is 5 or 6; and X is —N + (CH
- the use of the compound of the formula I according to the present invention results in increased sensitivity to antibiotic treatment.
- the present invention relates to a method for inhibiting or disrupting biofilm formation, or reducing biofilm, in an individual in need thereof, comprising administering to said individual a therapeutically effective amount of a compound of the formula I as defined in any one of the embodiments above, including the compounds wherein R 1 is —CH 2 —; R 2 and R 3 are H; and: (i) n is 5; R 4 and R 5 are —(CH 2 ) 2 —; and Y is 1-methyl-imidazolium-3-yl or —N + (CH 3 ) 3 ; (ii) n is 5; R 4 and R 5 are —(CH 2 ) 3 —; and Y is —P + (C 4 H 9 ) 3 ; (iii) n is 5; R 4 and R 5 are —(CH 2 ) 4 —; and Y is —N + (CH 3 ) 3 ; (iv) n is 6; R 4 and R 5 are —((CH 2 —;
- the chemical shifts are relative to residual HDO signal (at ⁇ 4.80 ppm for the 1 H NMR) when the solvent is D 2 O, to residual CHCl 3 signal (at ⁇ 7.26 ppm for the 1 H NMR and 77.2 ppm for the 13 C NMR) when the solvent is CDCl 3 , or to residual DMSO (at ⁇ 2.50 ppm for the 1 H NMR and 39.5 ppm for the 13 C NMR) when the solvent is DMSO.
- Determination of C, H, and N compositions were performed using the Perkin-Elmer 2400 series II Analyzer. High-resolution electrospray mass spectra were recorded on a Waters Synapt instrument.
- Trimethyl phosphine (1 M in THF, 9.0 mL, 9 mmol) was added to 8 a (0.15 g, 0.43 mmol) under argon atmosphere. The solution was refluxed for 24 hours in a pressure tube. The precipitate was filtered, washed with THF, and dried under vacuum to afford a white solid (0.15 g, 69%).
- Trimethylphosphine (1.0 M in THF, 2.2 mL, 2.2 mmol) was added to a solution of 9 a (0.10 g, 0.05 mmol) in acetonitrile (6.0 mL). The resulting mixture was refluxed in a pressure tube for 96 hours. After cooling to 25° C., the precipitate was filtered, washed with diethyl ether, and dried under vacuum to afford 29 as white solid (0.12 g, 86%).
- Triethylphosphine (1.0 M in THF, 2.2 mL, 2.2 mmol) was added to a solution of 9 a (0.10 g, 0.05 mmol) in dry acetonitrile (8.0 mL). The resulting mixture was refluxed in a pressure tube for 72 hours. After cooling to 25° C., diethyl ether was added to give a white precipitate. The precipitate was filtered, washed with diethyl ether, and dried under vacuum to afford 30 as white solid (68 mg, 41%).
- Biofilm formation was quantified by measuring the difference between absorbance of untreated and treated bacterial samples for each tested concentration of the compounds and the absorbance of appropriate blank well at 600 nm (A 600 ) using Tecan plate reader.
- the MBIC 50 was defined as the lowest concentration at which at least 50% reduction in biofilm formation was measured compared to untreated cells. Each concentration of compound was tested in five replicates, and three to six independent experiments were performed.
- Biofilm eradication activity of the tested compounds determined against mature 24-h-old biofilms was performed as previously described (Pompilio et al., 2015). Briefly, bacterial species were allowed to form biofilms in TSB+1% glucose medium in a 96-well flat-bottom microtiter plate by incubation for 24 hours at 37° C. in 5% CO 2 . Following the 24-h incubation, biofilm samples were washed twice with sterile DDW, then were exposed to 200 ⁇ L of the tested compounds prepared at concentrations of 2, 4, 8, 16, 32, 64, and 128 ⁇ g/mL in TSB+1% glucose medium. After incubation at 37° C.
- MBEC 50 biofilm eradication
- Rat red blood cell haemolysis assay A sample of rat red blood cells (2% w/w) were incubated with each of the tested compounds for 1 hours at 37° C. in 5% CO 2 using the double dilution method starting at a concentration of 256 ⁇ g/mL.
- the negative control was phosphate-buffered saline (PBS), and the positive control was 1% w/v solution of Triton X-100 (which induced 100% haemolysis).
- PBS phosphate-buffered saline
- Triton X-100 which induced 100% haemolysis
- the supernatant was removed and absorbance at 550 nm was measured using a microplate reader (SpectraMax-M2).
- the results are expressed as percentage of haemoglobin released relative to the positive control (Triton X-100). Experiments were performed in triplicate, and the results are an average of experiments in blood samples taken from at least two rats.
- pH stability assay Aqueous solutions of compounds 28 and 30 were treated with dilute HCl to obtain a pH of 2.3. Basic pH values of 10.7 and 10.2 of solutions of the compounds 28 and 30, respectively, were obtained by adding dilute ammonia solution. The solutions were kept at room temperature for 4 hours and then freeze-dried. The 1 H spectra recorded for all samples matched the 1 H HMR spectra of the respective compounds at pH 7.4. Biofilm inhibition studies were conducted with these compounds as described above.
- Mammalian cell toxicity assay A metabolic activity assay was performed to evaluate toxicity of compounds to human cells in culture as previously described (Omata et al., 2006). Briefly, human monocytic THP-1 cells (ATCC TIB 202) were maintained at 37° C. in 5% CO 2 in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 g/mL streptomycin, and 100 units/mL penicillin (all from Biological Industries, Beit HaEmek, Israel).
- FBS fetal bovine serum
- streptomycin 100 g/mL
- penicillin all from Biological Industries, Beit HaEmek, Israel.
- Cystic fibrosis human bronchi epithelial cells IB3-1 (ATCC CRL-2777) and HaCaT human skin keratinocytes were cultured in Dulbecco's Modified Eagle's Medium (DMEM) medium (Invitrogen) supplemented with 10% FBS, 2 mM glutamine, 100 units/mL penicillin, and 100 g/mL streptomycin.
- DMEM Dulbecco's Modified Eagle's Medium
- FBS Dulbecco's Modified Eagle's Medium
- 2 mM glutamine 100 units/mL penicillin
- streptomycin 100 g/mL
- Cells were plated in 96-well format (60,000 cells/well for THP1; 10,000 cells/well for IB3-1 and HaCaT) for 24 hours at 37° C., 5% CO 2 .
- compound 27 was added at final concentrations of 0, 0.73, 2.94, 11.74, and 46.96 ⁇ M to the appropriate wells.
- MBIC 50 mean IC 50 value for biofilm inhibition
- Table 1 The most impressive biofilm inhibition properties were observed for deca-trimethylammonium pillar[ 5 ]arene 21 and the deca-N-methyl-imidazolium pillar[ 5 ]arene 22 .
- the MBIC 50 values of these compounds against each of the tested biofilm-forming Gram-positive pathogens ranged from 0.4 to 6.4 ⁇ M. Inhibition of biofilm formation was selective for Gram-positive strains. None of the cationic pillararenes in this study inhibited the formation of biofilm by Gram-negative strains E. coli ATCC 25922 and P. aeruginosa PAO1.
- TMA-Cl and TMA-Br are tetramethylammonium chloride and tetramethylammonium bromide, respectively. Each value is a mean of at least three independent experiments each including five replicates of each concentration.
- Pillar[ 5 ]arene 5 which has carboxylic head groups that are negatively charged under physiological conditions, did not inhibit biofilm formation by any of the tested strains. This showed that the positive charge was important for the observed activity.
- TMA-Br tetramethylammonium bromide
- TMA-Cl tetramethylammonium chloride
- the effect of the halogen ion on the inhibition of biofilm formation in the tested strains was further examined by the preparation of compound 26; the chloride analogue of compound 21.
- Compounds 21 and 26 had very similar MBIC50 values against four of the tested strains (strains A, B, D, E; Table 1).
- the halogen ion type did affect the ability of pillararene 26 to inhibit S. aureus BAA/043 (strain C) and S. mutans ATCC 700610 (strain F) biofilm formation; for these strains, the MBIC50 values of compound 26 with the chloride counter ion were two- and four-fold higher than those of compound 21 with the bromide anion, respectively.
- Compound 27 was found to be the most potent inhibitor of biofilm formation of all the cationic pillararenes tested strains as summarized in Table 1 and demonstrated visually in FIG. 2 .
- the MBIC50 values of pillar[ 6 ]arene analogue 27 were from 2- to 5-fold lower for four of the tested biofilm forming Gram-positive pathogens; no significant difference in the inhibition of biofilm formation between 21 and 27 was observed in for S. aureus BAA/043 (strain C, Table 1).
- S. mutans ATCC 700610 however, compound 21 was slightly more active than 27 (strain F, Table 1).
- the dose-dependent biofilm inhibition ability of compounds 21-27 against E. faecalis ATCC 29212 and S. aureus subsp. aureus Rosenbach ATCC 33592 is presented in FIG. 3 .
- Pillararenes 21 and 27 the most potent inhibitors of biofilm formation, did not eradicate mature biofilms.
- the MIC values against the examined Gram-positive strains were higher than ⁇ 47 ⁇ M, at least 16-fold higher than the highest MBIC50 value measured for pillar[ 6 ]arene 27 against the tested strains. We therefore concluded that the observed inhibition of biofilm formation did not result from a bactericidal effect.
- the possibility that pillar[ 6 ]arene 27 had a bacteriostatic effect was examined by comparing the growth curves of two of Gram-negative strains ( E. coli ATCC 29522 and P. Aeruginosa PA01) and two Gram-positive strains ( S. aureus subsp. aureus Rosenbach ATCC 33592 and E.
- Rat red blood cells serve as a standard model for the evaluation of the ability of compounds to lyse mammalian cell membranes. Up to a concentration of 94 ⁇ M, none of the cationic pillararenes caused any measurable hemolysis of red blood cells obtained from laboratory rats following a previously reported protocol (Benhamou et al., 2015).
- the water-soluble cationic pillar[ 5 ]arene derivatives used in this study were synthesized by a four-step process (Scheme 3). Briefly, in the first step commercially available hydroquinone was alkylated with 1,3-dibromopropane using potassium carbonate in acetone to afford the monomer 8 a .
- the functionalized pillar[ 5 ]arene 9 a was obtained by the cyclization of monomer 8 a with paraformaldehyde and boron trifluoride diethyletherate in dichloroethane.
- cationic amphiphiles act as antimicrobial agents that kill bacteria (Kanazawa et al., 1993 and 1994; Cieniecka-RosIonkiewicz et al., 2005; Kurata et al., 2011; Xue et al., 2015). Therefore, to evaluate whether the inhibiting effect of compounds 25 and 28-30 on biofilm formation originated from a possible antimicrobial activity of these compounds we measured the minimal inhibitory concentrations (MICs) against the tested strains. The MIC values for compounds 25 and 28-30 were found to be 27, 23, 25 and 21 ⁇ M, respectively, more than 16 fold higher than the highest MBIC 50 values measured for these compounds against the two tested strains. These results demonstrate that the inhibition of biofilm formation by the phosphonium-decorated pillararenes 29 and 30 did not originate from antibacterial activity.
- the stability of a bioactive compound may affect the molecule performance.
- the stability of the new phosphonium and ammonium pillar[ 5 ]arene derivatives was evaluated by incubation for 4 hours in solutions at different pH values. Thereafter the materials were freeze dried, inspected by 1 H-NMR and tested for their biofilm inhibition properties. No significant decomposition was observed in the 1 H-NMR spectra recorded after exposure to acidic or alkaline pH ( FIG. 11 ). More importantly, the anti-biofilm activities of compounds 28 and 30 remained unchanged after these exposures as seen in Table 4 and FIG. 12 .
- the ammonium pillar[ 5 - 6 ]arene derivatives prepared are compounds 31, 32 and 33 and are shown in Scheme 4.
- Compound 31 is an ammonium pillar[ 5 ]arene derivative similar to compound 25, wherein the spacer represented by each one of the groups R 4 and R 5 in the formula I is —(CH 2 ) 6 — rather than —(CH 2 ) 3 — as in compound 25;
- compound 32 is an ammonium pillar[ 6 ]arene derivative similar to compound 27, wherein the spacer represented by each one of the groups R 4 and R 5 in the formula I is —(CH 2 ) 3 — rather than —(CH 2 ) 2 — as in compound 27;
- compound 33 is an ammonium pillar[ 6 ]arene derivative similar to compound 27, wherein the cation represented by the group Y in the formula I is 1-methyl-imidazolium-3-yl rather than —N + (CH 3 ) 3 as in compound 27.
- biofilm inhibition activity of each one of these compounds is shown in Table 5.
- the non-symmetric ammonium pillar[ 5 ]arene derivatives 34 and 35 (Table 5) were found to have biofilm inhibition activity that is remarkably lower than those of the cationic pillar[ 5 - 6 ]arene derivatives of the formula I exemplified in each one of the Studies herein, indicating that the presence of cationic groups in both sides of the compound, and possibly also a symmetric structure, are necessary for enabling the biofilm inhibition activity.
Abstract
Cationic pillar[n]arenes, e.g., positively charged poly-ammonium, poly-phosphonium and poly-imidazolium pillar[5-6]arene derivatives are capable of inhibiting or preventing biofilm formation, and facilitating existing biofilm decomposition. A composition for inhibiting or disrupting biofilm, e.g., bacterial or fungal biofilm, formation, or reducing biofilm, can include a pharmaceutically acceptable carrier, and a cationic pillar[n]ene.
Description
- The present invention relates to cationic pillar[n]arenes, e.g., cationic pillar[5-6]arenes, and uses thereof in inhibiting or disrupting biofilm formation, or reducing biofilm.
- Bacterial biofilms are defined as microbial communities (cities of microbes) that are held together by an extracellular matrix. In recent years, there is an increasing interest in bacterial biofilms as a result of the fact that in the majority of the cases biofilms lead to a dramatic enhancement in resistance to antimicrobial agents (Fux et al., 2005; Davies, 2003; Rabin et al., 2015). Compared with planktonic bacteria (bacteria that grow in suspension), biofilm forming bacteria can be up to almost three orders of magnitude less susceptible to antibiotics (Bottcher et al., 2013). Moreover, it was estimated that biofilms account for a large percentage of nosocomial and implanted device-derived microbial infections in patients (Davey and O'Toole, 2000).
- Biofilm matrices are composed of exo-polymeric substances (EPS) that are high-molecular weight compounds secreted by the bacteria into the extracellular environment and are crucial for the integrity of all biofilms (Bottcher et al., 2013; Davey and O'Toole, 2000). EPS components include polysaccharides also termed exo-polysaccharides, proteins, extracellular DNA, lipids and bacterial decomposition substances that are held together by a highly complex network of hydrogen bonds as well as ionic and van der Waals interactions between the different matrix components. The composition of biofilm matrices varies significantly amongst different bacterial strains; some matrices contain mainly exo-polysaccharides and some mainly proteins. Moreover, the structure of the proteins and the monosaccharide building blocks that compose exo-polysaccharides vary between different biofilm producing bacterial strains.
- Investigation of the biofilm formation process in the Gram negative Pseudomonas aeruginosa which is one of the major causes for lethal bacterial lung infections revealed a biofilm formation process that was generally defined as a five step sequence described in
FIG. 1 (Jennings et al., 2014). In the first stage, planktonic bacteria adhere to the surface on which the biofilm is about to form. At this point, most of the interactions with the surface are based on van-der Waals reversible forces and the bacterial cell can easily leave the surface back into the media. Once these weak initial interactions took place, in the second stage, the bacterial cells more permanently anchor themselves to the surface by a cell adhesion process that involves protein based interactions. In the third and fourth stages, additional bacterial cell layers adhere to the first layer and form micro colonies that continue to grow and mature by forming an extracellular matrix coating. In the final fifth stage, biofilm forming bacterial cells leave the mature biofilm into the environment and remain as planktonic bacteria or establish new biofilm colonies depending on the environmental conditions. - Clardy and coworkers previously reported a collection of synthetic guanidine- and bi-guanidine-based cationic amphiphiles that inhibited biofilm formation as well as eradicated existing biofilms of bacillus subtillis and Staphylococcus aureus strains (Bottcher et al., 2013). More recently, Wuest and coworkers reported a collection of quaternary ammonium amphiphiles (Jennings et al., 2014) that demonstrated antimicrobial activity against a collection of Gram positive and Gram negative bacterial strains. In addition, some of these cationic amphiphiles efficiently broke down existing biofilms of the two Gram positive pathogens Staphylococcus aureus and Enterococcus faecalis. However it was reported that these molecules are all hemolytic compounds exhibiting pronounced toxicity against mammalian cells (Jennings et al., 2014).
- Pillar[n]arenes, first reported in 2008 (Ogoshi et al., 2008), have symmetrical cylindrical structures and relatively large free volumes. Pillar[n]arenes can be obtained and functionalized by simple and high yield synthesis routes making them a versatile macrocycles for various applications. These macrocycles possess host-guest properties owing to their π-electron rich cavity and crown ether-like arrangement of oxygen atoms at both rims. Hence, in recent years, pillar[n]arenes have been used in host-guest chemistry and as sensors and were used to construct supramolecular polymers, interlocked molecules, and hybrid biomolecular materials (Ogoshi et al., 2008; Ogoshi and Yamagishi, 2014; Cragg and Sharma, 2012; Xue et al., 2012; Dong et al., 2014a; Chunju, 2014; Ogoshi et al., 2016; Ma et al., 2016; Liz et al., 2016; Shi et al., 2016; Ogoshi et al., 2015; Nierengarten et al., 2013; Li, 2014; Yang et al., 2014; Adiri et al., 2013; Zhang and Zhao, 2013; Yao et al., 2014; Dong et al., 2014b; Mao et al., 2016; Wang et al., 2015; Jie et al., 2014). Despite the significant attention that pillararenes have received from the chemical community, to date, their biological activity remains relatively unexplored.
- Despite the great need, there are currently no clinically approved small molecules that act as efficient inhibitors of biofilm formation and/or as eradicators of mature biofilms, without affecting bacterial cell viability. Identification of such small molecules will offer a much needed solution to biofilm infections while not affecting the important natural bacterial flora of the body. In addition, it is likely that the bacteria will not develop any defense mechanisms against such biofilm inhibitors or eradicators.
- In one aspect, the present invention provides a compound of the formula I:
-
- wherein
- R1 is —CR6R7—, wherein R6 and R7 each independently is H, halogen, —COR8, —COOR8, —OCOOR8, —OCON(R8)2, —CN, —NO2, —SR8, —OR8, —N(R8)2, —CON(R8)2, —SO2R8, —SO3H, —S(═O)R8, or (C1-C8)alkyl optionally substituted by one or more groups each independently selected from —COR8, —COOR8, —OCOOR8, —OCON(R8)2, —CN, —NO2, —SR8, —OR8, —N(R8)2, —CON(R8)2, —SO2R8, —SO3H, —S(═O)R8, —N+(R′)3 or —P+(R′)3, wherein R′ each independently is H, (C1-C6)alkyl, phenyl, benzyl, or heterocyclyl, or two R's together with the N atom to which they are attached form a 3-7 membered saturated ring, optionally containing one or more heteroatoms selected from O, S or N and optionally further substituted at the additional N atom;
- R2 and R3 each independently is H, halogen, or (C1-C8)alkyl optionally substituted by one or more groups each independently selected from halogen, —COR8, —COOR8, —OCOOR8, —OCON(R8)2, —CN, —NO2, —SR8, —OR8, —N(R8)2, —CON(R8)2, —SO2R8, —SO3H, —S(═O)R8, —N+(R′)3 or —P+(R′)3, wherein R′ each independently is H, (C1-C6)alkyl, phenyl, benzyl, or heterocyclyl, or two R's together with the N atom to which they are attached form a 3-7 membered saturated ring, optionally containing one or more heteroatoms selected from O, S or N and optionally further substituted at the additional N atom;
- R4 and R5 each independently is selected from (C1-C10)alkylene, (C2-C10)alkenylene, or (C2-C10)alkynylene, optionally substituted by one or more groups each independently selected from halogen, —COR8, —COOR8, —OCOOR8, —OCON(R8)2, —CN, —NO2, —SR8, —OR8, —N(R8)2, —CON(R8)2, —SO2R8, —SO3H, —S(═O)R8, (C6-C10)aryl, (C1-C4)alkylene-(C6-C10)aryl, heteroaryl, or (C1-C4)alkylene-heteroaryl, and further optionally interrupted by one or more identical or different heteroatoms selected from S, O or N, and/or at least one group each independently selected from —NH—CO—, —CO—NH—, —N(C1-C8alkyl)-, —N(C6-C10aryl)-, (C6-C10)arylenediyl, or heteroarylenediyl;
- R8 each independently is H or (C1-C8)alkyl;
- Y each independently is a cation derived from a nitrogen-containing group, a nitrogen-containing mono- or polycyclic heteroaromatic group optionally containing O, S or additional N atoms, or an onium group not containing nitrogen, linked to R4 or R5 via its positively charged atom;
- X is a counter anion such as Br−, Cl−, F−, I−, PF6 −, BF4 −, OH−, ClO4 −, HSO4 −, CF3COO−, CN−, alkylCOO−, arylCOO−, a pharmaceutically acceptable anion, or a combination thereof; and
- n is an integer of 5-11,
- but excluding the compounds wherein R1 is —CH2—; R2 and R3 are H; and: (i) n is 5; R4 and R5 are —(CH2)2—; and Y is 1-methyl-imidazolium-3-yl or —N+(CH3)3; (ii) n is 5; R4 and R5 are —(CH2)3—; and Y is —P+(C4H9)3; (iii) n is 5; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; (iv) n is 6; R4 and R5 are —(CH2)2—; and Y is —N+(CH3)3; (v) n is 6; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; (vi) n is 6; R4 and R5 are —(CH2)4—; and Y is 1-pyridinium; or (vii) n is 6; R4 and R5 are —(CH2)2—; and Y is 1-methyl-imidazolium-3-yl.
- More particularly, the invention provides a compound of the formula I as defined above, wherein Y each independently is (i) a cation derived from a nitrogen-containing group and selected from an ammonium [—N+(R′)3], hydrazinium [—N+(R′)2—N(R′)2], ammoniumoxy [—N+(R′)2—O], iminium [—N+(R′)2═C<], amidinium [—N+(R′)2—C(R′)═NR′], or guanidinium [—N+(R′)2—C(═NR′)—N(R′)2]; (ii) a cation derived from a nitrogen-containing mono- or polycyclic heteroaromatic group and selected from pyrazolium, imidazolium, oxazolium, thiazolium, pyridinium, pyrimidinium, quinolinium, isoquinolinium, 1,2,4-triazinium, 1,3,5-triazinium, or purinium, optionally substituted by one or more groups each independently selected from halogen, (C1-C6)alkyl, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, or —S(═O)H; or (iii) a cation derived from an onium group not containing nitrogen and selected from phosphonium [—P+(R′)3], arsonium [—As+(R′)3], oxonium [—O+(R′)2], sulfonium [—S+(R′)2], selenonium [—Se+(R′)2], telluronium [—Te+(R′)2], stibonium [—Sb+(R′)3], or bismuthonium [—Bi+(R′)3], wherein R′ each independently is H, (C1-C6)alkyl, phenyl, benzyl, or heterocyclyl, or two R's in the ammonium, hydrazinium, ammoniumoxy, iminium, amidinium or guanidinium groups, together with the N atom to which they are attached, form a 3-7 membered saturated ring, optionally containing one or more heteroatoms selected from O, S or N and optionally further substituted at the additional N atom.
- In another aspect, the present invention provides a composition comprising a compound of the formula I as defined above, i.e., excluding the compounds excluded by the proviso above, and a carrier.
- In a further aspect, the present invention relates to a method for inhibiting or disrupting biofilm formation in an aqueous media or on an object, or for reducing biofilm existing in an aqueous media or attached to an object, said method comprising contacting said aqueous media or object with a compound of the formula I, including the compounds excluded by the proviso above.
- In certain embodiments, the method of the present invention is for inhibiting or disrupting biofilm formation in an aqueous media, or for reducing biofilm existing in said aqueous media, and comprises in fact dissolving of said compound or a composition comprising it within said aqueous media. In other embodiments, the method of the present invention is for inhibiting or disrupting biofilm formation on an object, or for reducing biofilm attached to said object, and comprises coating of said object with said compound or a composition comprising it, or immersing of said object within a composition comprising said compound, respectively.
- In yet another aspect, the present invention relates to a pharmaceutical composition for inhibiting or disrupting biofilm, e.g., bacterial or fungal biofilm, formation, or reducing biofilm, said composition comprising a pharmaceutically acceptable carrier, and a compound of the formula I wherein X is a pharmaceutically acceptable anion, including the compounds excluded by the proviso above.
- In still another aspect, the present invention relates to a compound of the formula I, including the compounds excluded by the proviso above, for use in inhibiting or disrupting biofilm, e.g., bacterial or fungal biofilm, formation, or reducing biofilm.
- In yet a further aspect, the present invention relates to a method for inhibiting or disrupting biofilm formation, or reducing biofilm, in an individual in need thereof, comprising administering to said individual a therapeutically effective amount of a compound of the formula I, including the compounds excluded by the proviso above.
-
FIG. 1 illustrates the stages of biofilm formation process. -
FIG. 2 shows inhibition of biofilm formation by pillar[6]arene 27. Biofilms produced by S. aureus subsp. aureus Rosenbach ATCC 33592 (a) and by E. faecalis ATCC 29212 (b) in the presence of increasing concentrations of 27 were stained with crystal violet. Each concentration of compound was tested in five wells. -
FIGS. 3A-3B show biofilm formation by E. faecalis ATCC 29212 (3A) and S. aureus subsp. aureus Rosenbach ATCC 33592 (3B), evaluated using the double-dilution method with starter inoculum of 1:100 (OD60=0.01). Molarity concentration ranges of the tested compounds: (21) 0.22-28.18; (22) 0.20-25.59; (23) 0.18-23.78; (25) 0.21-26.54; (26) 0.27-35.00; and (27) 0.18-23.48 μM. No measurable biofilm inhibition effect was detected forcompounds -
FIGS. 4A-4C show the effect of initial inoculum on biofilm formation inhibition by compound 27. The compound was incubated with E. faecalis (ATCC 29212; right panels) and S. aureus subsp. aureus Rosenbach (ATCC 33592; left panels) at starter inoculums of OD600 0.025 (4A), 0.05 (4B), or 0.10 (4C). -
FIGS. 5A-5D show growth curves of bacteria in the presence of compound 27: (5A) E. coli ATCC 25922, (5B) P. aeruginosa PA01, (5C) E. faecalis ATCC 29212, and (5D) S. aureus subsp. aureus Rosenbach ATCC 33592. Bacteria were incubated with compound 27 (32 and 64 μg/mL) for 24 h at 37° C. Pillar[6]arene conjugate 27 did not inhibit the growth of these bacteria. -
FIGS. 6A-6B show the effect of compound 27 on the viability of IB3-1 cells (6A); and THP-1 cells (6B). -
FIG. 7 shows biofilms of S. aureus subsp. aureus Rosenbach ATCC 33592 in the presence of increasing concentrations (μM) of pillar[5]arene derivatives (a) compound 29, (b)compound 30, (c) compound 25, and (d)compound 28 stained with crystal violet. -
FIG. 8 shows biofilms formed by E. faecalis ATCC 29212 in the presence of increasing concentrations (μM) of pillar[5]arene derivatives (a) compound 29, (b)compound 30, (c) compound 25, and (d)compound 28 stained with crystal violet. -
FIG. 9 shows biofilms formed by S. aureus subsp. aureus Rosenbach ATCC 33592 in the presence of increasing concentrations of (a)compound 12 and (c)compound 11. Biofilms formed by E. faecalis ATCC 29212 in the presence of increasing concentrations of (b)compound 12 and (d)compound 11. All the wells were stained with crystal violet. -
FIGS. 10A-10C show biofilm formation by S. aureus ATCC 33592 (MRSA) (10A) and E. faecalis ATCC 29212 (10B) evaluated using the double-dilution method with starter inoculum of 1:100 (OD600=0.01) in the presence of compounds 25 and 28-30; and biofilm formation in the presence ofcompounds 11 and 12 (10C) Concentration ranges of the tested compounds were: (25) 0.21-13.27; (28) 0.18-11.30; (29) 0.19-12.40; (30) 0.17-10.66; (11) 5.3-340 μM; and (12) 4.95-317. -
FIGS. 11A-11B show 1H NMR spectra ofcompound 28 after incubation pH (a) 7.4, (b) 2.3, and (c) 10.2 for 4 hours (11A); and 1H NMR spectra ofcompound 30 after incubation at pH (a) 7.4, (b) 2.3, and (c) 10.7 for 4 hours (11B). -
FIGS. 12A-12B show biofilm formation by S. aureus subsp. aureus Rosenbach ATCC 33592 (12A) and E. faecalis ATCC 29212 (12B) in the presence of increasing concentrations (μM) 28 and 30 that had been incubated for 4 hours at different pH levels. -
FIGS. 13A-13B show the cell toxicity ofcompounds 25, 29 and 30 on mammalian IB3-1 cell-line (13A) and HaCaT cell-line (13B). - The present invention relates to cationic amphiphilic systems capable of interfering with the chemical interactions between different components of biofilm matrices, more particularly bacterial biofilm matrices, thereby inhibiting or preventing biofilm formation and facilitating existing biofilm decomposition without intervening with bacterial viability and damaging mammalian cell membranes as many families of cationic amphiphiles do.
- More specifically, the invention provides cationic pillararene derivatives such as positively charged poly-ammonium, poly-phosphonium and poly-imidazolium pillararene derivatives. These systems are water soluble organic salts containing both a lipophilic but relatively electron-rich cavity as well as two arrays of positively charged moieties of the two opposite faces of the pillararene backbone which can interact with the negatively charged membranes and other different molecular components of the biofilm matrices. The cationic ammonium/phosphonium pillar[5-6]arenes exemplified herein, including both known and novel compounds, were synthesized according to the procedures described in detail in the Experimental Section and depicted in Schemes 1-3 hereinafter, and are shown in
Scheme 4. - The novel cationic pillar[5-6]arene derivatives specifically disclosed herein are compounds of the formula I, wherein (i) n is 5; R1 is —CH2—; R2 and R3 are H; R4 and R5 are —(CH2)3—; and Y is —N+(CH3)3 or —P+(CH3)3, herein identified compound 25 and 29, respectively; (ii) n is 5; R1 is —CH2—; R2 and R3 are H; R4 and R5 are —(CH2)3—; and Y is —N+(C2H5)3 or —P+(C2H5)3, herein identified
compound compound 32. Additional cationic pillar[5-6]arene derivatives specifically exemplified are compounds of the formula I, wherein (i) n is 5; R1 is —CH2—; R2 and R3 are H; R4 and R5 are —(CH2)2—; and Y is —N+(CH3)3, —N+(C2H5)3, or 1-methyl-imidazolium-3-yl, herein identified compound 21 (or 26), 23 and 22, respectively; or (ii) n is 6; R1 is —CH2—; R2 and R3 are H; R4 and R5 are —(CH2)2—, and Y is —N+(CH3)3, or 1-methyl-imidazolium-3-yl, herein identified compound 27 and 33, respectively. In all those compounds, X is Br− or Cl−. - As has been found and shown herein, the water soluble cationic pillar[5-6]arene derivatives tested are extremely efficient in inhibiting biofilm formation at sub μM concentrations, without affecting the tested bacterial cell viability or causing measurable damage to the membranes of mammalian red blood cells (RBCs). The phosphonium-decorated pillararenes exhibited similar potencies as inhibitors of biofilm formation as their corresponding ammonium analogues, demonstrating that the number of positively charged groups and not their chemical identity are key to their anti-biofilm activity. The pillararene platform appears to be important and positive charges operating cooperatively are needed for effective anti-biofilm activity, as indicated by our finding that the respective cationic monomers were completely inactive. Interestingly, the cationic pillararene derivatives tested retained their anti-biofilm capability even after four hours of exposure to acidic or alkaline pH. The organisms in which the compounds were found to inhibit biofilm formation include clinical pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa and more.
- Such cationic pillararene derivatives can thus be used to fight biofilm formation and to eradicate existing biofilms in myriad of applications such as in water reservoirs, closed circuit water systems, in painting industries especially in dyes used to protect vessels from water, in toothpaste and dentistry industry, and more. The compounds may also be used to fight biofilm on surfaces in hospitals, medical devices and implants, as well as in external and internal pads and optionally in conjunction with antibiotic treatments.
- In one aspect, the present invention thus provides a compound of the formula I:
-
- wherein
- R1 is —CR6R7—, wherein R6 and R7 each independently is H, halogen, —COR8, —COOR8, —OCOOR8, —OCON(R8)2, —CN, —NO2, —SR8, —OR8, —N(R8)2, —CON(R8)2, —SO2R8, —SO3H, —S(═O)R8, or (C1-C5)alkyl optionally substituted by one or more groups each independently selected from —COR8, —COOR8, —OCOOR8, —OCON(R8)2, —CN, —NO2, —SR8, —OR8, —N(R8)2, —CON(R8)2, —SO2R8, —SO3H, —S(═O)R8, —N+(R′)3 or —P+(R′)3, wherein R′ each independently is H, (C1-C6)alkyl, phenyl, benzyl, or heterocyclyl, or two R's together with the N atom to which they are attached form a 3-7 membered saturated ring, optionally containing one or more heteroatoms selected from O, S or N and optionally further substituted at the additional N atom;
- R2 and R3 each independently is H, halogen, or (C1-C5)alkyl optionally substituted by one or more groups each independently selected from halogen, —COR8, —COOR8, —OCOOR8, —OCON(R8)2, —CN, —NO2, —SR8, —OR8, —N(R8)2, —CON(R8)2, —SO2R8, —SO3H, —S(═O)R8, —N+(R′)3 or —P+(R′)3, wherein R′ each independently is H, (C1-C6)alkyl, phenyl, benzyl, or heterocyclyl, or two R's together with the N atom to which they are attached form a 3-7 membered saturated ring, optionally containing one or more heteroatoms selected from O, S or N and optionally further substituted at the additional N atom;
- R4 and R5 each independently is selected from (C1-C10)alkylene, (C2-C10)alkenylene, or (C2-C10)alkynylene, optionally substituted by one or more groups each independently selected from halogen, —COR8, —COOR8, —OCOOR8, —OCON(R8)2, —CN, —NO2, —SR8, —OR8, —N(R8)2, —CON(R8)2, —SO2R8, —SO3H, —S(═O)R8, (C6-C10)aryl, (C1-C4)alkylene-(C6-C10)aryl, heteroaryl, or (C1-C4)alkylene-heteroaryl, and further optionally interrupted by one or more identical or different heteroatoms selected from S, O or N, and/or at least one group each independently selected from —NH—CO—, —CO—NH—, —N(C1-C8alkyl)-, —N(C6-C10aryl)-, (C6-C10)arylenediyl, or heteroarylenediyl;
- R8 each independently is H or (C1-C8)alkyl;
- Y each independently is (i) a cation derived from a nitrogen-containing group and selected from an ammonium [—N+(R′)3], hydrazinium [—N+(R′)2—N(R′)2], ammoniumoxy [—N+(R′)2→O], iminium [—N+(R′)2═C<], amidinium [—N+(R′)2—C(R′)═NR′], or guanidinium [—N+(R′)2—C(═NR′)—N(R′)2]; (ii) a cation derived from a nitrogen-containing mono- or polycyclic heteroaromatic group and selected from pyrazolium, imidazolium, oxazolium, thiazolium, pyridinium, pyrimidinium, quinolinium, isoquinolinium, 1,2,4-triazinium, 1,3,5-triazinium, or purinium, optionally substituted by one or more groups each independently selected from halogen, (C1-C6)alkyl, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, or —S(═O)H; or (iii) a cation derived from an onium group not containing nitrogen and selected from phosphonium [—P+(R′)3], arsonium [—As+(R′)3], oxonium [—O+(R′)2], sulfonium [—S+(R′)2], selenonium [—Se+(R′)2], telluronium [—Te+(R′)2], stibonium [—Sb+(R′)3], or bismuthonium [—Bi+(R′)3], wherein R′ each independently is H, (C1-C6)alkyl, phenyl, benzyl, or heterocyclyl, or two R's in the ammonium, hydrazinium, ammoniumoxy, iminium, amidinium or guanidinium groups, together with the N atom to which they are attached, form a 3-7 membered saturated ring, optionally containing one or more heteroatoms selected from O, S or N and optionally further substituted at the additional N atom;
- X is a counter anion such as Br−, Cl−, F−, I−, PF6 −, BF4 −, OH−, ClO4 −, HSO4 −, CF3COO−, CN−, alkylCOO−, arylCOO−, a pharmaceutically acceptable anion, or a combination thereof; and
- n is an integer of 5-11,
- but excluding the compounds wherein R1 is —CH2—; R2 and R3 are H; and: (i) n is 5; R4 and R5 are —(CH2)2—; and Y is 1-methyl-imidazolium-3-yl or —N+(CH3)3; (ii) n is 5; R4 and R5 are —(CH2)3—; and Y is —P+(C4H9)3; (iii) n is 5; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; (iv) n is 6; R4 and R5 are —(CH2)2—; and Y is —N+(CH3)3; (v) n is 6; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; (vi) n is 6; R4 and R5 are —(CH2)4—; and Y is 1-pyridinium; or (vii) n is 6; R4 and R5 are —(CH2)2—; and Y is 1-methyl-imidazolium-3-yl.
- The term “halogen” as used herein refers to a halogen and includes fluoro, chloro, bromo, and iodo, and it is preferably chloro or bromo.
- The term “alkyl” as used herein typically means a linear or branched saturated hydrocarbon radical having 1-8 carbon atoms and includes, e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isoamyl, 2,2-dimethylpropyl, n-hexyl, n-heptyl, n-octyl, and the like. Preferred are (C1-C6)alkyl groups, more preferably (C1-C4)alkyl groups, most preferably methyl, ethyl or propyl. The alkyl defined herein may optionally be substituted with one or more groups each independently selected from halogen, —COR, —COOR, —OCOOR, —OCON(R)2, —CN, —NO2, —SR, —OR, —N(R)2, —CON(R)2, —SO2R, —SO3R or —S(═O)R, wherein R is H or unsubstituted (C1-C5)alkyl.
- The term “alkylene” as used herein typically means a straight or branched divalent hydrocarbon radical having 1-10 carbon atoms, e.g., methylene, ethylene, propylene, butylene, 2-methylpropylene, pentylene, 2-methylbutylene, hexylene, 2-methylpentylene, 3-methylpentylene, 2,3-dimethylbutylene, heptylene, octylene, nonylene, decanylene, and the like. Preferred are (C1-C8)alkylene or (C1-C6)alkylene, more preferably (C1-C4)alkylene, most preferably methylene, ethylene, propylene, or butylene. The terms “alkenylene” and “alkynylene” typically mean straight or branched divalent hydrocarbon radicals having 2-10 carbon atoms, and one or more double or triple bonds, respectively.
- The term “aryl” denotes an aromatic carbocyclic group having 6-10 carbon atoms consisting of a single ring or condensed multiple rings such as, but not limited to, phenyl and naphthyl. The aryl defined herein may optionally be substituted with one or more groups each independently selected from halogen, —COR, —COOR, —OCOOR, —OCON(R)2, —CN, —NO2, —SR, —OR, —N(R)2, —CON(R)2, —SO2R, —SO3R, —S(═O)R, or —(C1-C5)alkyl, wherein R is H or unsubstituted (C1-C5)alkyl. The term “arylenediyl” refers to a divalent radical derived from an “aryl” as defined herein by removal of a further hydrogen atom from any of the ring atoms.
- The term “heterocyclic ring” denotes a mono- or poly-cyclic non-aromatic ring of 4-12 atoms containing at least one carbon atom and one to three heteroatoms selected from sulfur, oxygen or nitrogen, which may be saturated or unsaturated, i.e., containing at least one unsaturated bond. Preferred are 3- or 7-membered heterocyclic rings. The term “heterocyclyl” as used herein refers to any univalent radical derived from a heterocyclic ring as defined herein by removal of hydrogen from any ring atom. Examples of such radicals include, without limitation, piperidino, 4-morpholinyl, or pyrrolidinyl. The heterocyclyl defined herein may optionally be substituted, at any position of the ring, with one or more groups each independently selected from halogen, —COR, —COOR, —OCOOR, —OCON(R)2, —CN, —NO2, —SR, —OR, —N(R)2, —CON(R)2, —SO2R, —SO3R, —S(═O)R, or —(C1-C5)alkyl, wherein R is H or unsubstituted (C1-C5)alkyl.
- The term “heteroaryl” refers to a radical derived from a 5-10-membered mono- or poly-cyclic heteroaromatic ring containing 1-3, preferably 1-2, heteroatoms selected from nitrogen, sulfur or oxygen. Examples of mono-cyclic heteroaryls include, without being limited to, pyrrolyl, furyl, thienyl, thiazinyl, pyrazolyl, pyrazinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, 1,2,3-triazinyl, 1,3,4-triazinyl, and 1,3,5-triazinyl. Polycyclic heteroaryl radicals are preferably composed of two rings such as, but not limited to, benzofuryl, isobenzofuryl, benzothienyl, indolyl, quinolinyl, isoquinolinyl, imidazo[1,2-a]pyridyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, pyrido[1,2-a]pyrimidinyl and 1,3-benzodioxinyl. The heteroaryl may optionally be substituted by one or more groups each independently selected from halogen, —COR, —COOR, —OCOOR, —OCON(R)2, —CN, —NO2, —SR, —OR, —N(R)2, —CON(R)2, —SO2R, —SO3R, —S(═O)R, or —(C1-C5)alkyl, wherein R is H or unsubstituted (C1-C5)alkyl. It is to be understood that when a polycyclic heteroaryl is substituted, the substitution may be in any of the carbocyclic and/or heterocyclic rings. The term “heteroarylenediyl” denotes a divalent radical derived from a “heteroaryl” as defined herein by removal of a further hydrogen atom from any of the ring atoms.
- The term “cation derived from a nitrogen-containing group” as used herein denotes for example, but without limiting to, an ammonium [—N+(R′)3], hydrazinium [—N+(R′)2—N(R′)2], ammoniumoxy [—N+(R′)2→O], iminium [—N+(R′)2═C<], amidinium [—N+(R′)2—C(R′)═NR′], or guanidinium [—N+(R′)2—C(═NR′)—N(R′)2], wherein R′ each independently is H, (C1-C6)alkyl, phenyl, benzyl, or heterocyclyl, or two R's together with the N atom to which they are attached form a 3-7 membered saturated ring, optionally containing one or more heteroatoms selected from O, S or N and optionally further substituted at the additional N atom. In particular embodiments, the cation derived from a nitrogen-containing group is an ammonium as defined hereinabove.
- The term “cation derived from a nitrogen-containing mono- or polycyclic heteroaromatic group optionally containing O, S or additional N atoms” as used herein denotes for example, but without limiting to, pyrazolium, imidazolium, oxazolium, thiazolium, pyridinium, pyrimidinium, quinolinium, isoquinolinium, 1,2,4-triazinium, 1,3,5-triazinium, or purinium, optionally substituted by one or more groups each independently selected from halogen, (C1-C6)alkyl, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, or —S(═O)H;
- The term “cation derived from an onium group not containing nitrogen” as used herein denotes for example, but without limiting, phosphonium [—P+(R′)3], arsonium [—As+(R′)3], oxonium [—O+(R′)2], sulfonium [—S+(R′)2], selenonium [—Se+(R′)2], telluronium [—Te+(R′)2], stibonium [—Sb+(R′)3], or bismuthonium [—Bi+(R′)3], wherein R′ each independently is H, (C1-C6)alkyl, phenyl, benzyl, or heterocyclyl. In particular embodiments, the cation derived from an onium group not containing nitrogen is a phosphonium as defined hereinabove.
- In certain embodiments, the compound of the present invention is a compound of the formula I, wherein R1 is —CR6R7—, wherein R6 and R7 each independently is H, halogen, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, or (C1-C5)alkyl optionally substituted by one or more groups each independently selected from —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, —N+(R′)3 or —P+(R′)3, wherein R′ each independently is H, (C1-C4)alkyl, phenyl, or benzyl. Particular such compounds are those wherein R6 and R7 each independently is (C1-C5)alkyl, preferably (C1-C4)alkyl, or H. In preferred embodiments, R1 is —CH2—, i.e., R6 and R7 are each H.
- In certain embodiments, the compound of the present invention is a compound of the formula I, wherein R2 and R3 each independently is H, or (C1-C4)alkyl, preferably (C1-C2)alkyl, optionally substituted by one or more groups each independently selected from halogen, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, —N+(R′)3 or —P+(R′)3, wherein R′ each independently is H, (C1-C4)alkyl, phenyl, or benzyl. Particular such compounds are those wherein R2 and R3 each independently is (C1-C4)alkyl, preferably (C1-C2)alkyl, or H. In preferred embodiments, R2 and R3 are each H.
- In certain embodiments, the compound of the present invention is a compound of the formula I, wherein R4 and R5 each independently is (C2-C10)alkylene optionally substituted and further optionally interrupted as defined above. In particular such embodiments, R4 and R5 each independently is (C2-C10)alkylene, (C2-C8)alkylene or (C2-C6)alkylene, optionally substituted by one or more groups each independently selected from halogen, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, (C6)aryl, (C1-C4)alkylene-(C6)aryl, heteroaryl, or (C1-C4)alkylene-heteroaryl, and further optionally interrupted by one or more identical or different heteroatoms selected from S, O or N, and/or at least one group each independently selected from —NH—CO—, —CO—NH—, —N(C1-C8alkyl)-, —N(C6aryl)-, (C6)arylenediyl, or heteroarylenediyl. More particular such compounds are those wherein R4 and R5 each independently is (C2-C10)alkylene, (C2-C8)alkylene or (C2-C6)alkylene, optionally interrupted by one or more identical or different heteroatoms, preferably one or more O atoms.
- In certain embodiments, the compound of the present invention is a compound of the formula I, wherein R4 and R5 are identical.
- In certain embodiments, the compound of the present invention is a compound of the formula I, wherein Y each independently is (i) ammonium [—N+(R′)3] or phosphonium [—P+(R′)3], wherein R′ each independently is H, (C1-C6)alkyl, phenyl, benzyl, or heterocyclyl; or (ii) imidazolium, optionally substituted by one or more groups each independently selected from halogen, (C1-C6)alkyl, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, or —S(═O)H. Particular such compounds are those wherein Y each independently is ammonium [—N+(R′)3] or phosphonium [—P+(R′)3], wherein R′ each independently is H, methyl, ethyl, or propyl; or 1-methyl-imidazolium-3-yl.
- In certain embodiments, the compound of the present invention is a compound of the formula I, wherein n is an integer of 5, 6, 7 or 8, preferably 5 or 6.
- In certain embodiments, the compound of the present invention is a compound of the formula I, wherein (i) R1 is —CR6R7—, wherein R6 and R7 each independently is H, halogen, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, or (C1-C5)alkyl optionally substituted by one or more groups each independently selected from —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, —N+(R′)3 or —P+(R′)3, wherein R′ each independently is H, (C1-C4)alkyl, phenyl, or benzyl; (ii) R2 and R3 each independently is H, or (C1-C4)alkyl, preferably (C1-C2)alkyl, optionally substituted by one or more groups each independently selected from halogen, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, —N+(R′)3 or —P+(R′)3, wherein R′ each independently is H, (C1-C4)alkyl, phenyl, or benzyl; (iii) R4 and R5 each independently is (C2-C10)alkylene, (C2-C8)alkylene or (C2-C6)alkylene, optionally substituted by one or more groups each independently selected from halogen, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, (C6)aryl, (C1-C4)alkylene-(C6)aryl, heteroaryl, or (C1-C4)alkylene-heteroaryl, and further optionally interrupted by one or more identical or different heteroatoms selected from S, O or N, and/or at least one group each independently selected from —NH—CO—, —CO—NH—, —N(C1-C8alkyl)-, —N(C6aryl)-, (C6)arylenediyl, or heteroarylenediyl; and (iv) n is an integer of 5, 6, 7 or 8.
- In particular such embodiments, the compound of the invention is a compound of the formula I, wherein R1 is —CH2—; R2 and R3 are H; and R4 and R5 each independently is (C2-C10)alkylene, (C2-C8)alkylene or (C2-C6)alkylene, optionally interrupted by one or more 0 atoms. More particular such compounds are those wherein Y each independently is (i) ammonium [—N+(R′)3] or phosphonium [—P+(R′)3], wherein R′ each independently is H, (C1-C6)alkyl, phenyl, benzyl, or heterocyclyl, but preferably H, methyl, ethyl or propyl; or (ii) imidazolium, optionally substituted by one or more groups each independently selected from halogen, (C1-C6)alkyl, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, or —S(═O)H, but preferably 1-methyl-imidazolium-3-yl. In preferred such embodiments, n is an integer of 5 or 6.
- Specific cationic pillararenes according to the present invention, including those exemplified herein, are the compounds of the formula I, wherein R1 is —CH2—; R2 and R3 are H; X is a counter anion as defined above; and: (i) R4 and R5 are —(CH2)3—, or —(CH2)6—; Y is —N+(CH3)3, —N+(C2H5)3, —P+(CH3)3, or —P+(C2H5)3; and n is 5; or (ii) R4 and R5 are —(CH2)3—; Y is —N+(CH3)3, —P+(CH3)3, or 1-methyl-imidazolium-3-yl; and n is 6.
- The cationic pillararenes of the invention, also referred to herein as “biofilm inhibitors”, can be prepared by any suitable procedure and technology known in the art, e.g., as exemplified herein and depicted in detail in Schemes 1-3.
- In another aspect, the present invention provides a composition comprising a carrier and a compound of the formula I as defined in any one of the embodiments above, but excluding the compounds wherein R1 is —CH2—; R2 and R3 are H; and: (i) n is 5; R4 and R5 are —(CH2)2—; and Y is 1-methyl-imidazolium-3-yl or —N+(CH3)3; (ii) n is 5; R4 and R5 are —(CH2)3—; and Y is —P+(C4H9)3; (iii) n is 5; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; (iv) n is 6; R4 and R5 are —(CH2)2—; and Y is —N+(CH3)3; (v) n is 6; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; (vi) n is 6; R4 and R5 are —(CH2)4—; and Y is 1-pyridinium; or (vii) n is 6; R4 and R5 are —(CH2)2—; and Y is 1-methyl-imidazolium-3-yl. Such compositions may be inter alia pharmaceutical compositions, wherein said carrier is a pharmaceutically acceptable carrier, and the counter anion X is a pharmaceutically acceptable anion.
- In certain embodiments, the composition of the present invention comprises a compound selected from those specifically disclosed herein, i.e., a compound of the formula I, wherein R1 is —CH2—; R2 and R3 are H; X is a counter anion as defined above; and: (i) R4 and R5 are —(CH2)3—, or —(CH2)6—; Y is —N+(CH3)3, —N+(C2H5)3, —P+(CH3)3, or —P+(C2H5)3; and n is 5; or (ii) R4 and R5 are —(CH2)3—; Y is —N+(CH3)3, —P+(CH3)3, or 1-methyl-imidazolium-3-yl; and n is 6.
- In a further aspect, the present invention relates to a method for inhibiting or disrupting biofilm formation in an aqueous media or on an object, or for reducing biofilm existing in an aqueous media or attached to an object, said method comprising contacting said aqueous media or object with a compound of the formula I as defined in any one of the embodiments above, including the compounds wherein R1 is —CH2—; R2 and R3 are H; and: (i) n is 5; R4 and R5 are —(CH2)2—; and Y is 1-methyl-imidazolium-3-yl or —N+(CH3)3; (ii) n is 5; R4 and R5 are —(CH2)3—; and Y is —P+(C4H9)3; (iii) n is 5; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; (iv) n is 6; R4 and R5 are —(CH2)2—; and Y is —N+(CH3)3; (v) n is 6; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; (vi) n is 6; R4 and R5 are —(CH2)4—; and Y is 1-pyridinium; or (vii) n is 6; R4 and R5 are —(CH2)2—; and Y is 1-methyl-imidazolium-3-yl.
- In specific embodiments, the method of the present invention comprises contacting said aqueous media or object with a compound of the formula I, wherein R1 is —CH2—; R2 and R3 are H; R4 and R5 are identical and each one is —(CH2)2-10—, i.e., —(CH2)2, —(CH2)3, —(CH2)4, —(CH2)5, —(CH2)6, —(CH2)7, —(CH2)8, —(CH2)9, or —(CH2)10; Y is —N+(CH3)3, —N+(C2H5)3, —P+(CH3)3, —P+(C2H5)3, or 1-methyl-imidazolium-3-yl; n is 5 or 6; and X is a counter anion, wherein each one of the combinations of R1-R5, Y, n, and X defined herein represents a specific such compound.
- In certain embodiments, the method of the present invention is for inhibiting or disrupting biofilm formation in an aqueous media, i.e., a medium having water in it, or for reducing biofilm existing in said aqueous media, wherein said contacting comprises dissolving a compound of the formula I, or a composition comprising it, within said aqueous media.
- In certain embodiments, the method of the present invention is for inhibiting or disrupting biofilm formation on an object, or for reducing biofilm attached to said object, wherein said contacting comprises coating said object with a compound of the formula I, or a composition comprising it, or immersing said object within a composition comprising said compound, respectively. The object being “treated” according to the method of the present invention may be, without being limited to, an object designed for functioning in water, e.g., the hull of a boat, a pipe, a filter, a pump, or a heat-exchanger; a medical implant such as a stent; a medical device such as a catheter; or a biomedical pad such as an adhesive bandage. In particular such embodiments, the method of the present invention comprises coating said object with a composition comprising a compound of the formula I, i.e., with an antifouling composition such as antifouling paints and coatings for use inter alia in the food industry and hospitals. Such paints and coatings may be formulated, e.g., as sprays or hydrogels.
- In certain embodiments, the method of the present invention as defined in any one of the embodiments above results in increased sensitivity of said aqueous media or object to a bacteriocide, i.e., a substance that kills bacteria such as a disinfectant (an antimicrobial agent that is applied to non-living objects to destroy microorganisms that are living on the objects), antiseptic, or antibiotic, and optionally further comprises contacting said aqueous media or object with said bacteriocide. According to the present invention, the aqueous media or object “treated” by the method of the invention can be contacted with said compound of the formula I and said bacteriocide either at the same time (i.e., contacted with a combination of said compound of the formula I and said bacteriocide) or sequentially at any order.
- In yet another aspect, the present invention relates to a pharmaceutical composition for inhibiting or disrupting biofilm, e.g., bacterial or fungal biofilm, formation, or reducing biofilm, said composition comprising a pharmaceutically acceptable carrier, and a compound of the formula I as defined in any one of the embodiments above, including the compounds wherein R1 is —CH2—, R2 and R3 are H; and: (i) n is 5; R4 and R8 are —(CH2)2—; and Y is 1-methyl-imidazolium-3-yl or —N+(CH3)3; (ii) n is 5; R4 and R5 are —(CH2)3—; and Y is —P+(C4H9)3; (iii) n is 5; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; (iv) n is 6; R4 and R5 are —(CH2)2—; and Y is —N+(CH3)3; (v) n is 6; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; (vi) n is 6; R4 and R5 are —(CH2)4—; and Y is 1-pyridinium; or (vii) n is 6; R4 and R5 are —(CH2)2—; and Y is 1-methyl-imidazolium-3-yl, wherein X is a pharmaceutically acceptable anion, i.e., an anion capable of forming a pharmaceutically acceptable salt of said compound.
- Pharmaceutically acceptable anions include, without limiting, chloride, bromide, iodide, acetate, mesylate, esylate, maleate, fumarate, tartrate, bitartrate, sulfate, p-toluenesulfonate, benzenesulfonate, methanesulfonate, ethanedisulfonate (edisylate), ethanesulfonate (esylate), tosylate, benzoate, acetate, phosphate, carbonate, bicarbonate, succinate, and citrate. Multiple anions can be used in a single preparation if desired.
- In specific embodiments, the pharmaceutical composition of the present invention comprises a compound of the formula I, wherein R1 is —CH2—; R2 and R3 are H; R4 and R8 are identical and each one is —(CH2)2-10—, i.e., —(CH2)2, —(CH2)3, —(CH2)4, —(CH2)5, —(CH2)6, —(CH2)7, —(CH2)8, —(CH2)9, or —(CH2)10; Y is —N+(CH3)3, —N+(C2H5)3, —P+(CH3)3, —P+(C2H5)3, or 1-methyl-imidazolium-3-yl; n is 5 or 6; and X is a pharmaceutically acceptable anion, wherein each one of the combinations of R1-R5, Y, n, and X defined herein represents a specific such compound.
- The pharmaceutical compositions provided by the present invention may be prepared by conventional techniques, e.g., as described in Remington: The Science and Practice of Pharmacy, 19th Ed., 1995. The compositions can be prepared, e.g., by uniformly and intimately bringing the active agent, i.e., the compound of the formula I, into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired formulation. The compositions may be in liquid, solid or semisolid form and may further include pharmaceutically acceptable fillers, carriers, diluents or adjuvants, and other inert ingredients and excipients. In one embodiment, the pharmaceutical composition of the present invention is formulated as nanoparticles.
- The pharmaceutical compositions can be formulated for any suitable route of administration, e.g., for parenteral administration such as intravenous, intraarterial, intrathecal, intrapleural, intratracheal, intraperitoneal, intramuscular or subcutaneous administration, topical administration, oral or enteral administration, or for inhalation. In certain embodiments, these compositions are formulated for either topical administration or for inhalation.
- The pharmaceutical composition of the invention may be in the form of a sterile injectable aqueous or oleaginous suspension, which may be formulated according to the known art using suitable dispersing, wetting or suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent. Acceptable vehicles and solvents that may be employed include, without limiting, water, Ringer's solution and isotonic sodium chloride solution.
- The term “topical administration” as used herein refers to external application to, e.g., the skin, scalp, mucous membranes, teeth, and hair. Pharmaceutical compositions for topical administration may thus be in the form of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve, an ointment, a serum, an anhydrous stick, oil based sprays, oil-in-water emulsions or water-in-oil emulsions. In certain particular embodiments, the pharmaceutical composition of the invention is a dental composition formulated, e.g., as a mouthwash, toothpaste, a composition for root canal cleaning and disinfection, or a filling composition with biofilm inhibition/prevention properties. In other particular embodiments, the pharmaceutical composition of the invention is formulated for hygienic wash.
- Pharmaceutical compositions according to the present invention, when formulated for inhalation, may be administered utilizing any suitable device known in the art, such as metered dose inhalers, liquid nebulizers, dry powder inhalers, sprayers, thermal vaporizers, electrohydrodynamic aerosolizers, and the like.
- Pharmaceutical compositions according to the present invention, when formulated for administration route other than parenteral administration, may be in a form suitable for oral use, e.g., as tablets, troches, lozenges, aqueous, or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and may further comprise one or more agents selected from sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active agent(s) in admixture with non-toxic pharmaceutically acceptable excipients, which are suitable for the manufacture of tablets. These excipients may be, e.g., inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating and disintegrating agents, e.g., corn starch or alginic acid; binding agents, e.g., starch, gelatin or acacia; and lubricating agents, e.g., magnesium stearate, stearic acid, or talc. The tablets may be either uncoated or coated utilizing known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated using the techniques described in the U.S. Pat. Nos. 4,256,108, 4,166,452 and 4,265,874 to form osmotic therapeutic tablets for control release. The pharmaceutical composition of the invention may also be in the form of oil-in-water emulsion.
- The pharmaceutical compositions of the invention may be formulated for controlled release of the active agent. Such compositions may be formulated as controlled-release matrix, e.g., as controlled-release matrix tablets in which the release of a soluble active agent is controlled by having the active diffuse through a gel formed after the swelling of a hydrophilic polymer brought into contact with dissolving liquid (in vitro) or gastro-intestinal fluid (in vivo). Many polymers have been described as capable of forming such gel, e.g., derivatives of cellulose, in particular the cellulose ethers such as hydroxypropyl cellulose, hydroxymethyl cellulose, methylcellulose or methyl hydroxypropyl cellulose, and among the different commercial grades of these ethers are those showing fairly high viscosity. In other configurations, the compositions comprise the active agent formulated for controlled release in microencapsulated dosage form, in which small droplets of the active agent are surrounded by a coating or a membrane to form particles in the range of a few micrometers to a few millimeters.
- Another contemplated formulation is depot systems, based on biodegradable polymers, wherein as the polymer degrades, the active agent is slowly released. The most common class of biodegradable polymers is the hydrolytically labile polyesters prepared from lactic acid, glycolic acid, or combinations of these two molecules. Polymers prepared from these individual monomers include poly (D,L-lactide) (PLA), poly (glycolide) (PGA), and the copolymer poly (D,L-lactide-co-glycolide) (PLG).
- The pharmaceutical compositions of the invention can be provided in a variety of dosages, wherein the actual dose administered will depend on the state of the individual treated, and will be determined as deemed appropriate by the practitioner.
- In still another aspect, the present invention relates to a compound of the formula I as defined in any one of the embodiments above, including the compounds wherein R1 is —CH2—; R2 and R3 are H; and: (i) n is 5; R4 and R5 are —(CH2)2—; and Y is 1-methyl-imidazolium-3-yl or —N+(CH3)3; (ii) n is 5; R4 and R5 are —(CH2)3—; and Y is —P+(C4H9)3; (iii) n is 5; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; (iv) n is 6; R4 and R5 are —(CH2)2—; and Y is —N+(CH3)3; (v) n is 6; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; (vi) n is 6; R4 and R5 are —(CH2)4—; and Y is 1-pyridinium; or (vii) n is 6; R4 and R5 are —(CH2)2—; and Y is 1-methyl-imidazolium-3-yl, for use in inhibiting or disrupting biofilm formation, or reducing biofilm.
- In specific embodiments, the compound used for inhibiting or disrupting biofilm formation, or for reducing biofilm, is a compound of the formula I, wherein R1 is —CH2—; R2 and R3 are H; R4 and R5 are identical and each one is —(CH2)2-10—, i.e., —(CH2)2, —(CH2)3, —(CH2)4, —(CH2)5, —(CH2)6, —(CH2)7, —(CH2)8, —(CH2)9, or —(CH2)10; Y is —N+(CH3)3, —N+(C2H5)3, —P+(CH3)3, —P+(C2H5)3, or 1-methyl-imidazolium-3-yl; n is 5 or 6; and X is a pharmaceutically acceptable anion, wherein each one of the combinations of R1-R5, Y, n, and X defined herein represents a specific such compound.
- In certain embodiments, the use of the compound of the formula I according to the present invention results in increased sensitivity to antibiotic treatment.
- In yet a further aspect, the present invention relates to a method for inhibiting or disrupting biofilm formation, or reducing biofilm, in an individual in need thereof, comprising administering to said individual a therapeutically effective amount of a compound of the formula I as defined in any one of the embodiments above, including the compounds wherein R1 is —CH2—; R2 and R3 are H; and: (i) n is 5; R4 and R5 are —(CH2)2—; and Y is 1-methyl-imidazolium-3-yl or —N+(CH3)3; (ii) n is 5; R4 and R5 are —(CH2)3—; and Y is —P+(C4H9)3; (iii) n is 5; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; (iv) n is 6; R4 and R5 are —(CH2)2—; and Y is —N+(CH3)3; (v) n is 6; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; (vi) n is 6; R4 and R5 are —(CH2)4—; and Y is 1-pyridinium; or (vii) n is 6; R4 and R5 are —(CH2)2—; and Y is 1-methyl-imidazolium-3-yl. In certain embodiments, this method results in increased sensitivity of said individual to an antibiotic treatment, and optionally further comprises administering to said individual a therapeutically effective amount of said antibiotic.
- The invention will now be illustrated by the following non-limiting Examples.
- General methods. Starting materials were purchased from Sigma-Aldrich, Alfa Aesar, TCI, Cambridge Isotope Laboratories, and Bio-Lab Ltd. Chemical reactions were monitored by TLC (Merck,
silica gel 60 F254) and the compounds were purified by SiO2 flash chromatography (Merck Kieselgel 60). 1H and 13C NMR spectra were recorded on 400 and 500 MHz Bruker Avance NMR spectrometers at 25° C. Chemical shifts (6) are given in parts per million (ppm) and spin-spin coupling (J) is given in Hz. The chemical shifts are relative to residual HDO signal (at δ 4.80 ppm for the 1H NMR) when the solvent is D2O, to residual CHCl3 signal (at δ 7.26 ppm for the 1H NMR and 77.2 ppm for the 13C NMR) when the solvent is CDCl3, or to residual DMSO (at δ 2.50 ppm for the 1H NMR and 39.5 ppm for the 13C NMR) when the solvent is DMSO. Determination of C, H, and N compositions were performed using the Perkin-Elmer 2400 series II Analyzer. High-resolution electrospray mass spectra were recorded on a Waters Synapt instrument. - Compound 5 (Adiri et al. (2013). In the final step, to a solution of 4 (50 mg, 42 μmol) in water was added sodium hydroxide (17 mg, 0.42 mmol). The solvent was removed by evaporation to afford a white solid (59 mg, 100%). 1H NMR (D2O): δ 6.73 (s, ArH, 10H), 4.46 (d, J=16 Hz, ArCH2Ar, 10H), 4.21 (d, J=16 Hz, ArCH2Ar, 10H), 3.78 (s, ArOCH2COONa, 10H) ppm. 13C NMR: δ 178.7, 150.4, 129.7, 115.5, 68.8, 30.2 ppm.
- Compound 6a (Yao et al. (2012). Carbon tetrabromide (19.9 g, 60 mmol) was added in small portions to a solution of 1,4-bis(2-hydroxyethoxy)benzene (5.0 g, 25 mmol) and triphenylphosphine (15.7 g, 60 mmol) in anhydrous acetonitrile (0.12 L); the reaction mixture was kept at 0° C. during the addition. The resulting mixture was then warmed to 25° C. for 4 h under argon atmosphere. The product was precipitated by the addition of cold water (0.2 L), and the solid was filtered and washed with methanol/water (3:2, 3×100 mL). The product was recrystallized from methanol to obtain the title compound as white flake-like crystals (5.8 g, 71%). 1H NMR (400 MHz, CDCl3): δ 6.86 (s, ArH, 4H), 4.24 (t, J=6.2 Hz, ArOCH2CH2Br, 4H), 3.61 (t, J=6.3 Hz, ArOCH2CH2Br, 4H) ppm. 13C NMR (100 MHz, CDCl3): δ 152.9, 116.1, 68.8, 29.4 ppm.
- Compound 6b. Carbon tetrachloride (5.8 mL, 60 mmol) was added in small portions to a solution of 1,4-bis(2-hydroxyethoxy)benzene (5.0 g, 25 mmol) and triphenylphosphine (15.7 g, 60 mmol) in anhydrous acetonitrile (0.12 l), and the reaction mixture was kept at 0° C. during the addition. The resulting mixture was then warmed to 25° C. for 4.5 hours under argon atmosphere. The product was precipitated by the addition of cold water (0.2 l), and the solid was filtered and washed with methanol/water (3:2, 3×0.1 l). The product was recrystallized from methanol to obtain 6b as white solid (2.6 g, 44%). 1H NMR (CDCl3): δ 6.68 (s, ArH, 4H), 4.18 (t, J=5.7 Hz, ArOCH2CH2Cl, 4H), 3.78 (t, J=5.7 Hz, ArOCH2CH2Cl, 4H) ppm. 13C NMR: δ 152.9, 116.1, 68.9, 42.1 ppm.
- Compound 7a (Yao et al., 2012; Ogoshi et al., 2012). To a solution of 6a (4.0 g, 12 mmol) and paraformaldehyde (1.1 g, 37 mmol) in 1,2-dichloroethane (60 mL) was added BF3.OEt2 (3.5 g, 25 mmol). The reaction mixture was kept at 25° C. for 1 h under argon atmosphere. The reaction mixture was washed with water (2×50 mL) and dried with sodium sulfate and concentrated in vacuo. The product was purified by chromatography (silica gel; petroleum ether:dichloromethane) to afford 7 a as a white solid (1.58 g, 38%). 1H NMR (400 MHz, CDCl3): δ 6.90 (s, ArH, 10H), 4.22 (t, J=5.7 Hz, ArOCH2CH2Br, 20H), 3.84 (s, ArCH2Ar, 10H), 3.62 (t, J=5.7 Hz, ArOCH2CH2Br, 20H) ppm. 13C NMR (100 MHz, CDCl3): δ 149.8, 129.2, 116.2, 69.1, 30.9, 29.5 ppm.
- Compound 7b. To a solution of 6b (2.0 g, 8.5 mmol) and paraformaldehyde (0.76 g, 25 mmol) in 1,2-dichloroethane (30 mL) was added BF3.OEt2 (2.4 g, 17 mmol). The reaction mixture was kept at 25° C. under argon atmosphere for 1 hour. The reaction mixture was washed with water (2×50 mL), brine (2×50 mL) and dried with sodium sulfate. The product was purified by column chromatography (silica gel; petroleum ether:dichloromethane) to afford 7 b as white solid (1.1 g, 52%). 1H NMR (CDCl3): δ 6.91 (s, ArH, 10H), 4.15 (t, J=5.5 Hz, ArOCH2CH2Cl, 20H), 3.83 (s, ArCH2Ar, 10H), 3.80 (t, J=5.5 Hz, ArOCH2CH2Cl, 20H) ppm. 13C NMR: δ 149.8, 129.1, 115.9, 69.1, 43.2, 29.4 ppm.
- Compound 8a (Whiteside et al., 2002). A mixture of hydroquinone (8.0 g, 73 mmol), 1,3-dibromopropane (44 g, 0.22 mol), and potassium carbonate (45 g, 0.33 mol) were refluxed in acetone (0.13 L) for 24 hours under argon atmosphere. The reaction mixture was cooled to 25° C. and filtered through celite, and the solvent was evaporated under vacuum. The residue was dissolved in dichloromethane (0.1 L), washed with water (2×50 mL), 3N HCl (2×50 mL), and brine (2×50 mL), dried with sodium sulphate, and concentrated in vacuo. The product was purified by column chromatography (silica gel; eluent: hexane/ethyl acetate). Further purification by recrystallization in ethyl acetate/hexane afforded 8 a as a white solid (9.5 g, 37%). 1H NMR (400 MHz, CDCl3): δ 6.84 (s, ArH, 4H), 4.05 (t, J=5.9 Hz, ArOCH2CH2CH2Br, 4H), 3.60 (t, J=6.7 Hz, ArOCH2CH2CH2Br, 4H), 2.29 (m, ArOCH2CH2CH2Br, 4H) ppm. 13C NMR (100 MHz, CDCl3): δ 153.0, 115.5, 65.9, 32.5, 30.2 ppm.
- Compound 9a (Ogoshi et al., 2012). To a solution of 8 a (2.5 g, 7.1 mmol) in 1,2-dichloroethane (60 mL) was added paraformaldehyde (0.67 g, 22 mmol) followed by BF3.OEt2 (1.1 g, 7.8 mmol). The reaction mixture was kept at 30° C. for 30 min under argon atmosphere. The resulting mixture was cooled to 25° C., and the crude product was precipitated by addition of methanol (0.2 L). The product was purified by chromatography (silica gel; hexane:dichloromethane) to afford the title compound as a white solid (1.1 g, 43%). 1H NMR (400 MHz, CDCl3): δ 6.74 (s, ArH, 10H), 3.99 (t, J=6.3 Hz, ArOCH2CH2CH2Br, 20H), 3.75 (s, ArCH2Ar, 10H), 3.52 (t, J=6.5 Hz, ArOCH2CH2CH2Br, 20H), 2.21 (m, ArOCH2CH2CH2Br, 20H) ppm. 13C NMR (100 MHz, CDCl3): δ 149.8, 128.5, 115.3, 66.3, 32.7, 30.5, 29.9 ppm.
- Compound 10a. To a solution of 6a (2.5 g, 7.7 mmol) and paraformaldehyde (0.46 g, 15 mmol) in chloroform (0.12 mL) was added BF3.OEt2 (2.19 g, 15 mmol). The reaction mixture was kept at 25° C. under argon atmosphere for 3 hours. The reaction mixture was washed with water (2×100 mL), brine (2×100 mL) and dried with sodium sulfate. The product was purified by column chromatography (silica gel; petroleum ether:dichloromethane) to afford 10 a as white solid (0.38 g, 15%). 1H NMR (D2O): δ 6.78 (s, ArH, 12H), 4.16 (t, J=6.2 Hz, ArOCH2CH2Br, 24H), 3.86 (s, ArCH2Ar, 12H), 3.55 (t, J=6.2 Hz, ArOCH2CH2Br, 24H) ppm. 13C NMR: δ 150.3, 128.6, 115.9, 69.1, 30.7, 30.4 ppm.
-
Compound 11. Trimethylamine (33% in ethanol, 1.0 mL, 5.7 mmol) was added to a solution of 8 a (0.2 g, 0.57 mmol) in ethanol (5 mL). The resulting mixture was refluxed in a pressure tube for 24 hours. After cooling to 25° C., the precipitate was filtered, washed with ethanol, and dried under vacuum to afford white solid (0.26 g, 97%). 1H NMR (400 MHz, D2O): δ 6.96 (s, ArH, 4H), 4.11 (t, J=5.8 Hz, ArOCH2, 4H), 3.52 (m, CH2CH2N, 4H), 3.12 (s, N(CH3)3, 18H), 2.24 (m, ArOCH2CH2, 4H) ppm. 13C NMR (125 MHz, D2O): δ 153.1, 117.0, 66.2, 64.7, 53.7, 23.4 ppm. HRMS: m/z calcd. for C18H34O2N2Br3 [M+Br]− 547.0170, found 547.0181. -
Compound 12. Trimethyl phosphine (1 M in THF, 9.0 mL, 9 mmol) was added to 8 a (0.15 g, 0.43 mmol) under argon atmosphere. The solution was refluxed for 24 hours in a pressure tube. The precipitate was filtered, washed with THF, and dried under vacuum to afford a white solid (0.15 g, 69%). 1H NMR (400 MHz, D2O): 7.00 (s, ArH, 4H), 4.12 (t, J=5.8 Hz, ArOCH2, 4H), 2.42-2.34 (m, ArOCH2CH2, 4H), 2.09-2.04 (m, CH2P(CH3)3, 4H), 1.86 (d, J=14.3 Hz, P(CH3)3, 18H) ppm. 13C NMR (100 MHz, D2O): δ 153.1, 117.0, 68.6 (d, J=16 Hz), 21.7, 21.2 (d, J=54 Hz), 8.0 (d, J=55 Hz) ppm. 31P NMR (162 MHz, D2O, H3PO4 reference): δ 27.3 ppm. HRMS: m/z calcd. for C18H34O2P2Br3 [M+Br]− 580.9584, found 580.9599. - Compound 21 (Ma et al., 2011). In the final step, trimethylamine (33% in ethanol, 6.4 mL, 24 mmol) was added to a solution of 7 a (1.0 g, 0.59 mmol) in ethanol (50 mL). The resulting mixture was refluxed for 24 hours. After cooling to 25° C., the solvent was removed under vacuum and the residue was dissolved in water (20 mL). The solution was filtered and the solvent was removed by evaporation to afford colorless solid (1.2 g, 89%). 1H NMR (D2O): δ 6.97 (s, ArH, 10H), 4.48 (s, ArOCH2CH2N, 20H), 3.95 (s, ArCH2Ar, 10H), 3.83 (s, ArOCH2CH2N, 20H), 3.24 (s, N(CH3)3, 90H) ppm. 13C NMR: δ 150.36, 130.93, 117.49, 65.88, 64.46, 55.05, 30.56 ppm.
- Compound 22 (Yao et al., 2012; Ogoshi et al., 2012). In the final step, a mixture of 7 a (1.2 g, 0.76 mmol) and N-methylimidazole (1.2 g, 15 mmol) in toluene was kept at 120° C. for 24 hours. After cooling to 25° C., the solvent was removed under vacuum and the residue was recrystallized from ethanol/diethyl ether (1:2) to afford a white solid (1.8 g, 98%). 1H NMR (D2O): δ 8.4 (br, Imidazole-H, 10H) 7.63 (s, Imidazole-H, 10H), 7.15 (s, ArH, 10H), 6.76 (s, Imidazole-H, 10H), 4.64 (s, Ar—OCH2CH2, 20H), 4.47 (s, ArOCH2CH2, 20H), 3.66 (s, Imidazole-CH3, 30H), 3.62 (s, ArCH2Ar, 10H) ppm. 13C NMR: δ 150.08, 137.31, 129.94, 124.64, 123.46, 116.26, 67.79, 50.25, 36.64, 29.92 ppm.
- Compound 23. An excess amount of triethylamine (5.0 mL, 36 mmol) was added to a solution of 7 a (0.46 g, 0.27 mmol) in ethanol (5.0 mL). The resulting mixture was refluxed in a pressure tube for 5 days. After cooling to 25° C., the product was precipitated by the addition of diethyl ether. The precipitate was filtered, and the solid was washed with diethyl ether and acetone to remove excess triethylamine. The solid was dissolved in water and concentrated to afford a colorless solid that turned to thick oil when exposed to air (0.40 g, 54%). 1H NMR (400 MHz, DMSO-d6): δ 7.00 (s, ArH, 10H), 4.52 (br, ArOCH2CH2N, 20H), 3.98 (br, ArOCH2CH2N, 20H), 3.75 (s, ArCH2Ar, 10H), 3.51 (br, NCH2CH3, 60H), 1.26 (t, NCH2CH3, J=7.1 Hz, 90H) ppm. 13C NMR (100 MHz, CDCl3): δ 148.8, 128.3, 115.5, 62.1, 55.8, 53.1, 28.7, 7.7 ppm.
-
Compound 24. 2-Dimethylaminoethanol (0.85 g, 9.5 mmol) was added to a solution of 7 a (0.20 g, 0.12 mmol) in ethanol. The resulting mixture was refluxed for 48 hours. After cooling to 25° C., the solvent was removed under vacuum and the residue was dissolved in water (5.0 mL). The solution was filtered and the solvent was removed by evaporation. Finally the residue was washed with ethanol and dried under vacuum to afford a light brown solid (0.22 g, 71%). 1H NMR (D2O): δ 6.96 (s, ArH, 10H), 4.55 (br, ArOCH2CH2, 20H), 4.07-3.97 (ArCH2Ar, ArOCH2CH2N & NCH2CH2OH, 50H), 3.65 (br, NCH2CH2OH, 20H), 3.30 (s, N(CH3)2, 60H) ppm. 13C NMR: δ 150.5, 131.0, 117.6, 67.5, 65.0, 64.5, 56.6, 50.5, 30.8 ppm. - Compound 25. Trimethylamine (33% in ethanol, 0.79 mL, 4.4 mmol) was added to a solution of 9 a (0.20 g, 0.11 mmol) in ethanol (10 mL). The resulting mixture was refluxed for 24 hours. After cooling to 25° C., the solvent was removed under vacuum and the residue was dissolved in water (5.0 mL). The solution was filtered and the solvent was removed by evaporation. The residue recrystallized as light brown crystals in ethanol (0.21 g, 79%). 1H NMR (D2O): δ 6.78 (s, ArH, 10H), 3.90 (br, ArOCH2CH2CH2 & ArCH2Ar, 30H), 3.39 (br, ArOCH2CH2CH2, 20H), 3.10 (br, N(CH3)3, 90H), 2.07 (br, ArOCH2CH2CH2, 20H) ppm. 13C NMR: δ 150.5, 129.9, 116.9, 66.6, 64.4, 53.6, 30.8, 23.4 ppm.
- Compound 26. Prepared similarly to compound 21 by reacting 7 b (0.15 g, 0.12 mmol) with trimethylamine (33% in ethanol, 3.0 mL, 11 mmol) in acetonitrile for 48 h; white solid (0.17 g, 78%). δ 1H NMR (400 MHz, D2O): δ 6.98 (s, ArH, 10H), 4.48 (s, ArOCH2CH2N, 20H), 3.95 (s, ArCH2Ar, 10H), 3.84 (s, ArOCH2CH2N, 20H), 3.25 (s, N(CH3)3, 90H) ppm. 13C NMR (100 MHz, D2O): δ 150.1, 130.7, 117.2, 65.5, 64.1, 54.7, 30.2 ppm.
- Compound 27. Prepared similarly to compound 21 by reacting 10 a (0.15 g, 74 μmol) with trimethylamine (33% in ethanol, 0.70 mL, 3.7 mmol); white solid (0.16 g, 73%). 1H NMR (500 MHz, D2O): δ 6.94 (s, ArH, 12H), 4.54 (t, J=4.9 Hz, ArOCH2CH2N, 24H), 3.98 (s, ArCH2Ar, 12H), 3.78 (t, J=4.8 Hz, ArOCH2CH2N, 24H), 3.15 (s, N(CH3)3, 108H) ppm. 13C NMR (125 MHz, D2O): δ 150.3, 129.6, 116.7, 65.6, 63.9, 54.5, 30.6 ppm.
-
Compound 28. An excess amount of triethyl amine (5.0 mL, 36 mmol) was added to a solution of 9 a (0.40 g, 0.22 mmol) in ethanol (5.0 mL). The resulting mixture was refluxed in a pressure tube for 7 days. After cooling to 25° C., the product was precipitated by the addition of diethyl ether. The precipitate was filtered, and the solid was washed with diethyl ether and acetone. The product was sonicated in acetone (5×10 mL) to remove excess triethyl amine. Finally the solid was dissolved in water and concentrated to afford a white solid (0.42 g, 68%). 1H NMR (400 MHz, DMSO-d6): δ 6.80 (s, ArH, 10H), 4.19 & 3.89 (br, ArOCH2CH2CH2N, 20H), 3.73 (s, ArCH2Ar, 10H), 3.44 (br, ArOCH2CH2CH2N, 20H), 3.43 (br, NCH2CH3, 60H), 2.22 (br, ArOCH2CH2CH2, 20H), 1.26 (t, J=7.0 Hz, NCH2CH3, 90H) ppm. 13C NMR (100 MHz): δ 148.7, 127.9, 113.7, 65.0, 53.6, 52.3, 28.7, 22.4, 7.4 ppm. Anal. calcd. for C125H230Br10N10O10.10.75H2O: C, 49.62; H, 8.38; N, 4.63. Found: C, 49.31; H, 8.06; N, 4.46. - Compound 29. Trimethylphosphine (1.0 M in THF, 2.2 mL, 2.2 mmol) was added to a solution of 9 a (0.10 g, 0.05 mmol) in acetonitrile (6.0 mL). The resulting mixture was refluxed in a pressure tube for 96 hours. After cooling to 25° C., the precipitate was filtered, washed with diethyl ether, and dried under vacuum to afford 29 as white solid (0.12 g, 86%). 1H NMR (400 MHz, DMSO-d6): δ 6.85 (s, ArH, 10H), 4.07 & 3.90 (br, ArOCH2CH2CH2P, 20H), 3.78 (s, ArCH2Ar, 10H), 2.69-2.60 (m, CH2P(CH3)3, 20H), 2.00 (d, J=14.7 Hz, CH2P(CH3)3& ArOCH2CH2CH2P, 110H) ppm. 13C NMR (125 MHz, DMSO-d6): δ 148.7, 127.8, 114.1, 67.5 (d, J=17 Hz), 28.7, 21.7, 19.7 (d, J=56 Hz), 7.5 (d, J=55 Hz) ppm. 31P NMR (162 MHz, DMSO-d6, H3PO4 reference): δ 30.0 ppm. HRMS: m/z calcd. for C95H170O10P10Br11 [M+Br]− 2662.1098, found 2662.1116.
-
Compound 30. Triethylphosphine (1.0 M in THF, 2.2 mL, 2.2 mmol) was added to a solution of 9 a (0.10 g, 0.05 mmol) in dry acetonitrile (8.0 mL). The resulting mixture was refluxed in a pressure tube for 72 hours. After cooling to 25° C., diethyl ether was added to give a white precipitate. The precipitate was filtered, washed with diethyl ether, and dried under vacuum to afford 30 as white solid (68 mg, 41%). 1H NMR (500 MHz, DMSO-d6): δ 6.81 (s, ArH, 10H), 4.15 & 3.84 (br, ArOCH2CH2CH2P, 20H), 3.76 (s, ArCH2Ar, 10H), 2.61-2.55 (m, CH2P(CH2CH3)3, 20H), 2.46-2.39 (m, P(CH2CH3)3, 60H), 2.06 (m, OCH2CH2CH2, 20H), 1.23-1.17 (m, P(CH2CH3)3, 90H) ppm. 13C NMR (125 MHz, DMSO-d6): δ 148.7, 127.9, 113.8, 67.5 (d, J=16 Hz), 28.8, 21.7, 14.1 (d, J=50 Hz), 10.8 (d, J=48 Hz), 5.4 (d, J=5 Hz) ppm. 31P NMR (162 MHz, D2O, H3PO4 reference): δ 39.8 ppm. Anal. calcd. for C125H230Br10P10O10.14.45H2O: C, 45.77; H, 7.74. Found: C, 46.02; H, 8.00. HRMS: m/z calcd. for C125H230O10P10Br11 [M+Br]− 3081.5760, found 3081.5796. - Analysis of bacterial growth. The assay was performed as previously described (Feldman et al., 2012) with minor modifications. Briefly, all tested bacterial strains were grown from the frozen stock in Brain Heart Infusion (BHI) broth for 24 hours at 37° C. in 5% CO2. Next, 100 μL of serial 1:2 dilutions of compounds in Tryptic Soy Broth (TSB)+1% glucose (32, 16, 8, 4, 2, 1, and 0.5 μg/mL) were prepared in a flat-bottomed 96-well microplates (Costar, Corning). Control wells with no compound and wells without bacteria containing each tested concentration of the compounds (blanks) were also prepared. An equal volume (100 μL) of bacterial suspension diluted 1:100 (OD600=0.01) or 1:10 (OD600=0.1) in TSB+1% glucose was added to each well. During a 24 hours incubation at 37° C., growth kinetics were monitored by recording optical density at wavelength 600 nm (OD600) using a Tecan plate reader. Each concentration was tested in triplicates, and experiments were repeated three times.
- Analysis of biofilm inhibition. The assay was performed as previously described (Joseph et al., 2016; Feldman et al., 2012) with minor modifications. Briefly, all tested bacterial strains were grown from the frozen stock in BHI broth for 24 hours at 37° C. in 5% CO2. Next, 100 μL of serial 1:2 dilutions of compounds in TSB+1% glucose (32, 16, 8, 4, 2, 1, and 0.5 μg/mL) were prepared in flat-bottomed 96-well microplates (Costar, Corning). Control wells with no compounds and wells without bacteria containing each tested concentration of the compounds (blanks) were also prepared. An equal volume (100 μL) of bacterial suspensions diluted 1:100 (OD600=0.01) or 1:10 (OD600=0.1) in TSB+1% glucose was added to each well. After incubation for 24 hours at 37° C. in 5% CO2 under aerobic conditions, spent media and free-floating bacteria were removed by turning over the plates. The wells were vigorously rinsed at least four times with doubly distilled water (DDW). Next, 0.4% crystal violet (200 μL) was added to each well. After 45 min, wells were vigorously rinsed three times with DDW to remove unbound dye. After adding 200 μL of 30% acetic acid to each well, the plate was shaken for 15 min to release the dye. Biofilm formation was quantified by measuring the difference between absorbance of untreated and treated bacterial samples for each tested concentration of the compounds and the absorbance of appropriate blank well at 600 nm (A600) using Tecan plate reader. The MBIC50 was defined as the lowest concentration at which at least 50% reduction in biofilm formation was measured compared to untreated cells. Each concentration of compound was tested in five replicates, and three to six independent experiments were performed.
- Analysis of biofilm eradication. Biofilm eradication activity of the tested compounds determined against mature 24-h-old biofilms was performed as previously described (Pompilio et al., 2015). Briefly, bacterial species were allowed to form biofilms in TSB+1% glucose medium in a 96-well flat-bottom microtiter plate by incubation for 24 hours at 37° C. in 5% CO2. Following the 24-h incubation, biofilm samples were washed twice with sterile DDW, then were exposed to 200 μL of the tested compounds prepared at concentrations of 2, 4, 8, 16, 32, 64, and 128 μg/mL in TSB+1% glucose medium. After incubation at 37° C. in 5% CO2 for 24 h, non-adherent bacteria were removed by washing twice with sterile DDW, and biofilm samples were stained with crystal violet as described for biofilm inhibition assay. Untreated biofilm samples were used as control. Biofilms were quantified by measuring the absorbance at 600 nm. The mean IC50 value for biofilm eradication (MBEC50) was defined as the lowest concentration at which at least 50% reduction in biomass of preformed biofilms was measured compared to untreated biofilm samples. Concentrations were tested in five replicates, and three independent experiments were performed.
- Rat red blood cell haemolysis assay. A sample of rat red blood cells (2% w/w) were incubated with each of the tested compounds for 1 hours at 37° C. in 5% CO2 using the double dilution method starting at a concentration of 256 μg/mL. The negative control was phosphate-buffered saline (PBS), and the positive control was 1% w/v solution of Triton X-100 (which induced 100% haemolysis). Following centrifugation (2000 rpm, 10 min, ambient temperature), the supernatant was removed and absorbance at 550 nm was measured using a microplate reader (SpectraMax-M2). The results are expressed as percentage of haemoglobin released relative to the positive control (Triton X-100). Experiments were performed in triplicate, and the results are an average of experiments in blood samples taken from at least two rats.
- pH stability assay. Aqueous solutions of
compounds compounds - Mammalian cell toxicity assay. A metabolic activity assay was performed to evaluate toxicity of compounds to human cells in culture as previously described (Omata et al., 2006). Briefly, human monocytic THP-1 cells (ATCC TIB 202) were maintained at 37° C. in 5% CO2 in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 g/mL streptomycin, and 100 units/mL penicillin (all from Biological Industries, Beit HaEmek, Israel). Cystic fibrosis human bronchi epithelial cells IB3-1 (ATCC CRL-2777) and HaCaT human skin keratinocytes were cultured in Dulbecco's Modified Eagle's Medium (DMEM) medium (Invitrogen) supplemented with 10% FBS, 2 mM glutamine, 100 units/mL penicillin, and 100 g/mL streptomycin. Cells were plated in 96-well format (60,000 cells/well for THP1; 10,000 cells/well for IB3-1 and HaCaT) for 24 hours at 37° C., 5% CO2. In
Study 1, compound 27 was added at final concentrations of 0, 0.73, 2.94, 11.74, and 46.96 μM to the appropriate wells. InStudy 2, compounds were added at final concentrations of 2, 4, 8, 16, 32, 64 and 128 μg/ml to the appropriate wells. Wells without compounds served as controls. Plates were incubated for 1 hour, 24 hours, and 72 hours at 37° C. in 5% CO2. Cell viability was determined using MTT (3-[4,5-dimethylthiazoyl-2-yl]-2,5-diphenyl tetrazolium bromide) assay (Wataha et al., 1992), and cells were observed using light microscopy. The percentage of cell death was determined relative to vehicle-treated cells. Experiments were performed in triplicate, and the results were obtained from two independent experiments. - In the present study, we prepared five positively charged pillar[5]arene derivatives in which the 10 phenolic positions were substituted by positively charged quaternary ammonium or imidazolium groups (compounds 21-25), and as a control, we prepared the negatively charged pillar[5]
arene 5, which is decorated with 10 carboxylate groups that are negatively charged under physiological conditions. The compounds were synthesized following synthetic routes similar to those previously described (Ma et al., 2011; Yao et al., 2012; Adiri et al., 2013). - Each compound was tested for its ability to inhibit biofilm formation by Gram-positive and Gram-negative pathogens. The mean IC50 value for biofilm inhibition (MBIC50) was defined as the lowest concentration at which at least 50% reduction in biofilm formation was measured compared to untreated cells. The results are summarized in Table 1. The most impressive biofilm inhibition properties were observed for deca-trimethylammonium pillar[5]arene 21 and the deca-N-methyl-imidazolium pillar[5]
arene 22. The MBIC50 values of these compounds against each of the tested biofilm-forming Gram-positive pathogens ranged from 0.4 to 6.4 μM. Inhibition of biofilm formation was selective for Gram-positive strains. None of the cationic pillararenes in this study inhibited the formation of biofilm by Gram-negative strains E. coli ATCC 25922 and P. aeruginosa PAO1. -
TABLE 1 Biofilm inhibitory activity of certain pillar[5-6]arenes: MBIC50 (μM) against Gram-positive strains* Bacterial strain Compound A B C D E F 21 0.9 3.5 3.5 0.9 3.5 1.8 22 0.8 1.6 1.6 0.4 3.2 6.4 23 1.5 5.9 5.9 1.5 5.9 5.9 24 >12 >12 >12 >12 >12 >12 25 1.7 6.6 >13 1.7 1.7 6.6 26 1.1 4.4 8.8 1.1 2.2 8.8 27 0.4 1.5 2.9 0.4 0.7 2.9 5 >23 >23 >23 >23 >23 >23 TMA-Cl >292 >292 >292 >292 >292 >292 TMA-Br >208 >208 >208 >208 >208 >208 *Compounds were evaluated using the double-dilution method for inhibition biofilm formation by (A) S. aureus subsp. aureus Rosenbach ATCC 33592, (B) S. aureus ATCC 29213, (C) S. aureus BAA/043, (D) E. faecalis ATCC 29212, (E) S. epidermidis RP62A, (F) S. mutans ATCC 700610. TMA-Cl and TMA-Br are tetramethylammonium chloride and tetramethylammonium bromide, respectively. Each value is a mean of at least three independent experiments each including five replicates of each concentration. - Changes in the hydrophilic or hydrophobic balance of the cationic pillar[5]arene had general and significant effects on the inhibition of biofilm formation. Elongation of the aliphatic linker between the pillar[5]arene core and the positively charged group from an ethyl in compound 21 to a propyl chain in compound 25 led to a small but significant reduction in the inhibition of biofilm formation. A similar effect was observed when the quaternary tri-methyl ammonium head groups in compound 21 were replaced by more hydrophobic tri-ethyl quaternary ammonium groups in compound 23. A more pronounced loss of activity was observed when the hydrophilicity of the head groups was increased by the installation of hydroxyethyl-di-methyl quaternary ammonium groups in
compound 24;compound 24 did not inhibit biofilm formation at a concentration of 12 μM, the highest concentration tested. - To further evaluate the structural determinants required for biofilm formation inhibition, we examined anti-biofilm activities of several control compounds: Pillar[5]
arene 5, which has carboxylic head groups that are negatively charged under physiological conditions, did not inhibit biofilm formation by any of the tested strains. This showed that the positive charge was important for the observed activity. No inhibition of biofilm formation, up to concentrations of 292 μM and 208 μM, was observed for tetramethylammonium bromide (TMA-Br) or tetramethylammonium chloride (TMA-Cl), respectively, indicating that neither the quaternary ammonium head groups nor the halogen ions alone are responsible for the inhibition of biofilm formation by compounds 21-25. - The effect of the halogen ion on the inhibition of biofilm formation in the tested strains was further examined by the preparation of compound 26; the chloride analogue of compound 21. Compounds 21 and 26 had very similar MBIC50 values against four of the tested strains (strains A, B, D, E; Table 1). The halogen ion type did affect the ability of pillararene 26 to inhibit S. aureus BAA/043 (strain C) and S. mutans ATCC 700610 (strain F) biofilm formation; for these strains, the MBIC50 values of compound 26 with the chloride counter ion were two- and four-fold higher than those of compound 21 with the bromide anion, respectively.
- Since 21 demonstrated potent inhibition of biofilm formation by all tested strains of Gram-positive pathogens, we reasoned that increasing the quaternary ammonium cluster size and the overall positive charge of the molecule would further improve the inhibition properties. Hence, we synthesized compound 27, the pillar[6]arene analogue of 21. Compared to compound 21 the overall positive charge of compound 27 is 20% higher. Furthermore, the internal cavity diameter of pillar[6]arene 27 is ˜6.7 Å, whereas that of pillar[5]arene 21 is ˜4.6 Å (Ogoshi and Yamagishi, 2014). This difference should, in principle, enable compound 27 to bind larger and more structurally diverse molecular guests from the biofilm matrix. Compound 27 was found to be the most potent inhibitor of biofilm formation of all the cationic pillararenes tested strains as summarized in Table 1 and demonstrated visually in
FIG. 2 . Compared to pillar[5]arene 21, the MBIC50 values of pillar[6]arene analogue 27 were from 2- to 5-fold lower for four of the tested biofilm forming Gram-positive pathogens; no significant difference in the inhibition of biofilm formation between 21 and 27 was observed in for S. aureus BAA/043 (strain C, Table 1). For S. mutans ATCC 700610, however, compound 21 was slightly more active than 27 (strain F, Table 1). The dose-dependent biofilm inhibition ability of compounds 21-27 against E. faecalis ATCC 29212 and S. aureus subsp. aureus Rosenbach ATCC 33592 is presented inFIG. 3 . - Pillararenes 21 and 27, the most potent inhibitors of biofilm formation, did not eradicate mature biofilms. In addition, we determined the MBIC50 of compound 27, which demonstrated potent biofilm inhibition properties, against S. aureus subsp. aureus Rosenbach ATCC 33592, and E. faecalis in cultures that were 2-fold, 4-fold, and 10-fold the standard inoculum (OD=0.001). No significant change in MBIC50 values was observed indicating that there is no significant inoculum effect for this compound (
FIG. 4 ; Table 2). -
TABLE 2 Effect of initial inoculum on MBIC50 values of compound 27 Initial inoculum MBIC50 Bacteria strain (OD600) [μM] S. aureus subsp. aureus 0.025 0.37 Rosenbach ATCC 33592 0.05 0.37 0.1 0.37 E. faecalis (ATCC 29212) 0.025 0.37 0.05 0.73 0.1 0.73 - Since all of the pillararenes in this study are cationic amphiphiles, we evaluated the antimicrobial activity of the most potent inhibitor of biofilm formation pillar[6]arene 27 to determine whether the capability to inhibit biofilm formation results from bactericidal activity. Minimal inhibitory concentration (MIC) experiments were performed following the double-dilution protocol (Wiegand et al., 2008; Berkov-Zrihen et al., 2013).
- The MIC values against the examined Gram-positive strains were higher than ˜47 μM, at least 16-fold higher than the highest MBIC50 value measured for pillar[6]arene 27 against the tested strains. We therefore concluded that the observed inhibition of biofilm formation did not result from a bactericidal effect. The possibility that pillar[6]arene 27 had a bacteriostatic effect was examined by comparing the growth curves of two of Gram-negative strains (E. coli ATCC 29522 and P. Aeruginosa PA01) and two Gram-positive strains (S. aureus subsp. aureus Rosenbach ATCC 33592 and E. faecalis ATCC 29212) in the absence and in the presence of 32 and 64 μg/ml of 27 for 24 hours. These concentrations are ˜15 and ˜30-fold higher than the MBIC50 values measured for this compound against the two Gram-positive strains. The growth curves clearly indicated that, at a concentration significantly higher than the MBIC50, this compound had no effect on bacterial growth (
FIG. 5 ). Thus, the anti-Gram-positive biofilm properties of this compound do not result from a bacteriostatic effect. - Finally, many families of antimicrobial cationic amphiphiles disrupt mammalian cell membranes as well as bacterial cell membranes (Berkov-Zrihen et al., 2015; Benhamou et al., 2015). Rat red blood cells serve as a standard model for the evaluation of the ability of compounds to lyse mammalian cell membranes. Up to a concentration of 94 μM, none of the cationic pillararenes caused any measurable hemolysis of red blood cells obtained from laboratory rats following a previously reported protocol (Benhamou et al., 2015). The toxicity of compound 27 toward human monocytic THP1 cells (ATCC TIB 202) and cystic fibrosis human bronchial epithelial cells IB3-1 (ATCC CRL-2777) was also evaluated. No effects on viability were observed after 72-hour incubation with concentrations up to 46.96 μM, about 50 times the MBIC50 values measured for this compound against the two Gram-positive strains (
FIG. 6 ). - In the present study, we prepared a series of phosphonium and ammonium decorated pillar[5]arenes (25, 28-30) and their respective monomers (11 and 12) and studied their anti-biofilm activity with the aim of evaluating the effect of the nature of the positive charges; the cooperativity of the overall positive charges; and the pillar[n]arene platform on the observed anti-biofilm activity.
- The water-soluble cationic pillar[5]arene derivatives used in this study were synthesized by a four-step process (Scheme 3). Briefly, in the first step commercially available hydroquinone was alkylated with 1,3-dibromopropane using potassium carbonate in acetone to afford the monomer 8 a. The functionalized pillar[5]arene 9 a was obtained by the cyclization of monomer 8 a with paraformaldehyde and boron trifluoride diethyletherate in dichloroethane. Reaction of 9 a with an excess of trimethylamine or trimethylamine in ethanol under reflux gave the water-soluble pillar[5]
arene derivatives 25 or 28, respectively, and a similar procedure was followed to obtaincompounds 29 and 30, by reaction with excess of trimethylphosphine or triethylphosphine, respectively (Scheme 4). Thecontrol monomers - The effects of compounds 25 and 28-30 were evaluated on biofilm formation by two clinically important Gram-positive bacterial strains, S. aureus ATCC 33592 and Enterococcus faecalis ATCC 29212. Inhibition of biofilm formation was determined using the crystal violet staining assay (Feldman et al., 2012). The minimal concentration at which at least 50% reduction in biofilm formation compared to untreated cells (MBIC50) was determined, and the results are summarized in Table 3. The dose responses are presented in
FIGS. 7-10 . - All the cationic pillar[5]arene derivatives exhibited potent inhibition of biofilm formation against the two tested Gram-positive pathogens. The MBIC50 values of the deca-ammonium pillar[5]
arene analogues 25 and 28 were found to be in the range of 0.71-1.66 μM for both of the tested strains. The corresponding deca-phosphonium pillar[5]arenes 29 and 30 showed a similar range of MBIC50 values, 0.67-1.55 μM. These results indicate that replacement of the ammonium cations by phosphonium cations does not significantly affect the inhibition of biofilm formation by cationic pillararenes. Thus, the positive charges are essential for the observed anti-biofilm activity; however, the nature of the charges has a marginal effect. In this respect,Study 1 shows that a negatively charged deca-carboxylate derivative of pillar[5]arene does not significantly inhibit biofilm formation. -
TABLE 3 The anti-biofilm activity (MBIC50) of pillar[5]arene derivatives 25 and 28-30* MBIC50 in μM (μg/mL) S. aureus E. faecalis Compound ATCC 33592 ATCC 29212 25 1.66 (4) 1.66 (4) 28 0.71 (2) 1.41 (4) 29 1.55 (4) 1.55 (4) 30 1.33 (4) 0.67 (2) 11 >340 (160) >340 (160) 12 >317 (160) >317 (160) *Compounds were evaluated using the double-dilution method. Each value is the mean of at least three independent experiments that included five replicates at each concentration. - To evaluate the effect of hydrophobicity on the biofilm inhibition activity, we compared compounds 28 and 30, in which the ammonium or phosphonium cations are attached to triethyl moieties, to compounds 25 and 29, which carry trimethyl moieties. Despite the fact that
compounds FIGS. 7A-7B ). In addition, we found that the dose response for the tested pillar[5]arene derivatives 25 and 28-30 (FIGS. 7A-7B ) were also very similar, further corroborating the fact that pillararenes 28 and 30 are as effective as 25 and 29 in preventing biofilm formation by the two tested strains. - To understand the cumulative effect of the positive charges and the advantage of clustering these charges on a pillararene scaffold, we synthesized the
monomers Compounds Monomers FIG. 7C ), suggesting that in these anti-biofilm agents the cumulative charge organization on the pillar[5]arene scaffold is a crucial factor for the observed activity. - Many cationic amphiphiles act as antimicrobial agents that kill bacteria (Kanazawa et al., 1993 and 1994; Cieniecka-RosIonkiewicz et al., 2005; Kurata et al., 2011; Xue et al., 2015). Therefore, to evaluate whether the inhibiting effect of compounds 25 and 28-30 on biofilm formation originated from a possible antimicrobial activity of these compounds we measured the minimal inhibitory concentrations (MICs) against the tested strains. The MIC values for compounds 25 and 28-30 were found to be 27, 23, 25 and 21 μM, respectively, more than 16 fold higher than the highest MBIC50 values measured for these compounds against the two tested strains. These results demonstrate that the inhibition of biofilm formation by the phosphonium-decorated
pillararenes 29 and 30 did not originate from antibacterial activity. - The stability of a bioactive compound may affect the molecule performance. To address this issue the stability of the new phosphonium and ammonium pillar[5]arene derivatives was evaluated by incubation for 4 hours in solutions at different pH values. Thereafter the materials were freeze dried, inspected by 1H-NMR and tested for their biofilm inhibition properties. No significant decomposition was observed in the 1H-NMR spectra recorded after exposure to acidic or alkaline pH (
FIG. 11 ). More importantly, the anti-biofilm activities ofcompounds FIG. 12 . -
TABLE 4 Biofilm inhibitory activity against Gram positive strains of compounds 20 and 22 after incubation at different pH levels for 4 hours MBIC50 in μM (μg/mL) S. aureus subsp. aureus E. faecalis Compound pH Rosenbach ATCC 33592 ATCC 29212 28 2.3 1.41 (4) 1.41 (4) 7.4 1.41 (4) 1.41 (4) 10.7 1.41 (4) 1.41 (4) 30 2.3 0.67 (2) 1.33 (4) 7.4 0.67 (2) 1.33 (4)) 10.2 1.33 (4) 0.67 (2) - Finally, it is well established that many cationic amphiphiles disrupt mammalian cell membranes, which limits potential for clinical utility (Jennings et al., 2014). We therefore determined the haemolytic effect of pillar[5]arenes 29 and 30 on rat RBCs. Up to a concentration of 85 μM, none of the phosphonium-decorated pillar[5]arenes caused measurable haemolysis of RBCs. In addition, compounds 25, 29 and 30 were found to have no effect on mammalian cell viability up to a concentration of 128 μg/mL as shown in
FIG. 13 . - In this study, several ammonium pillar[5-6]arene derivatives other than those exemplified in Studies 1-2 were synthesized, utilizing chemical procedures similar to those exemplified above, and their biofilm inhibition activity was tested as described in the Studies above, using S. aureus ATCC 33592 (MRSA) and E. faecalis ATCC 29212.
- The ammonium pillar[5-6]arene derivatives prepared are
compounds 31, 32 and 33 and are shown inScheme 4. Compound 31 is an ammonium pillar[5]arene derivative similar to compound 25, wherein the spacer represented by each one of the groups R4 and R5 in the formula I is —(CH2)6— rather than —(CH2)3— as in compound 25;compound 32 is an ammonium pillar[6]arene derivative similar to compound 27, wherein the spacer represented by each one of the groups R4 and R5 in the formula I is —(CH2)3— rather than —(CH2)2— as in compound 27; and compound 33 is an ammonium pillar[6]arene derivative similar to compound 27, wherein the cation represented by the group Y in the formula I is 1-methyl-imidazolium-3-yl rather than —N+(CH3)3 as in compound 27. - The biofilm inhibition activity of each one of these compounds is shown in Table 5. Interestingly, the non-symmetric ammonium pillar[5]arene derivatives 34 and 35 (Table 5) were found to have biofilm inhibition activity that is remarkably lower than those of the cationic pillar[5-6]arene derivatives of the formula I exemplified in each one of the Studies herein, indicating that the presence of cationic groups in both sides of the compound, and possibly also a symmetric structure, are necessary for enabling the biofilm inhibition activity.
-
TABLE 5 The anti-biofilm activity (MBIC50) of pillar[5-6]arene derivatives 31-33 MBIC50 in μM (μg/mL) Compound MRSA E. faecalis 31 0.4 0.4 32 0.7 0.7 33 0.7 0.7 34 8.6 8.6 35 >15 >15 -
- Adiri, T.; Marciano, D.; Cohen, Y., Chem. Commun., 2013, 49, 7082-7084
- Benhamou, R. I.; Shaul, P.; Herzog, I. M.; Fridman, M., Angew. Chem. Int. Ed., 2015, 54, 13617
- Berkov-Zrihen, Y.; Herzog, I. M.; Feldman, M.; Sonn-Segev, A.; Roichman, Y.; Fridman, M., Bioorg. Med. Chem., 2013, 21, 3624
- Berkov-Zrihen, Y.; Herzog, I. M.; Benhamou, R. I.; Feldman, M.; Steinbuch, K. B.; Shaul, P.; Lerer, S.; Eldar, A.; Fridman, M., Chem. Eur. J., 2015, 21, 4340
- Bottcher, T.; Kolodkin-Gal, I.; Kolter, R.; Losick, R.; Clardy, J., J. Am. Chem. Soc., 2013, 135, 2927
- Chunju, L., Chem. Commun., 2014, 50, 12420-12433
- Cieniecka-RosIonkiewicz, A.; Pernak, J.; Kubis-Feder, J.; Ramani, A.; Robertson, A. J.; Seddon, K. R., Green Chem. 2005, 7, 855-862
- Costerton, J. W.; Stewart, P. S.; Greenberg, E. P., Science, 1999, 284, 1318-1322
- Cragg, P. J.; Sharma, K., Chem. Soc. Rev., 2012, 41, 597-607
- Davey, M. E.; O'Toole, G. A., Microbiol. Mol. Biol. Rev., 2000, 64, 847
- Davies, D., Nat. Rev. Drug. Discovery, 2003, 2, 114
- Dong, S.; Zheng, B.; Wang, F.; Huang, F., Acc. Chem. Res., 2014a, 47, 1982-1994
- Dong, S.; Yuan, J.; Huang, F., Chem. Sci. 2014b, 5, 247-252
- Feldman, M.; Tanabe, S.; Howell, A.; Garnier, D., BMC Complement. Altern. Med., 2012, 12, 6
- Fux, C. A.; Costerton, J. W.; Stewart, P. S.; Stoodley, P., Trends Microbiol., 2005, 13, 34
- Jennings M. C.; Ator, L. E.; Paniak, T. J.; Minbiole K. P. C.; Wuest, W. M., ChemBioChem, 2014, 15, 2211-2215
- Jie, K.; Yao, Y.; Chi, X.; Huang, F., Chem. Commun. 2014, 50, 5503-5505
- Joseph, R.; Naugolny, A.; Feldman, M.; Herzog, I. M.; Fridman, M.; Cohen, Y., J. Am. Chem. Soc., 2016, 138, 754-757
- Kanazawa, A.; Ikeda, T.; Endo, T., J. Polym. Sci. Part A Polym. Chem. 1993, 31, 335-343
- Kanazawa, A.; Ikeda, T.; Endo, T., Antimicrob. Agents Chemother., 1994, 38, 945-952
- Kurata, S.; Hamada, N.; Kanazawa, A.; Endo, T., Dent. Mater. J. 2011, 30, 960-966
- Li, C., Chem. Commun., 2014, 50, 12420-12433
- Liz, D. G.; Manfredi, A. M.; Medeiros, M.; Montecinos, R.; Gomez-Gonzalez, B.; Garcia-Rio, L.; Nome, F., Chem. Commun., 2016, 52, 3167-3170
- Ma, Y.; Ji, X.; Xiang, F.; Chi, X.; Han, C.; He, J.; Abliz, Z.; Chen, W.; Huang, F., Chem. Commun., 2011, 47, 12340
- Ma, Y. J.; Cheng, L.; Li, C.; Mullen, K., Chem. Commun., 2016, 52, 6662-6664
- Mao, X.; Liu, T.; Bi, J.; Luo, L.; Tian, D.; Li, H., Chem. Commun. 2016, 52, 4385-4388
- Nierengarten, I.; Nothisen, M.; Sigwalt, D.; Biellmann, T.; Holler, M.; Remy, J. S.; Nierengarten, J. F., Chem. Eur. J., 2013, 19, 17552-17558
- Ogoshi, T.; Kanai, S.; Fujinami, S.; Yamagishi, T.; Nakamoto, Y., J. Am. Chem. Soc., 2008, 130, 5022-5023
- Ogoshi, T.; Ueshima, N.; Yamagishi, T.; Toyota, Y.; Matsumi, N., Chem. Commun., 2012, 48, 3536-3538
- Ogoshi, T.; Yamagishi, T., Chem. Commun., 2014, 50, 4776-4787
- Ogoshi, T.; Takashima, S.; Yamagishi, T., J. Am. Chem. Soc., 2015, 137, 10962-10964
- Ogoshi, T.; Akutsu, T.; Shimada, Y.; Yamagishi, T., Chem. Commun., 2016, 52, 6479-6481
- Omata, Y.; Folan, M.; Shaw, M.; Messer, R. L.; Lockwood, P. E.; Hobbs, D.; Bouillaguet, S.; Sano, H.; Lewis, J. B.; Wataha, J. C., Toxicol In Vitro. 2006, 20, 882-890
- Pompilio, A.; Nicola, S. D.; Crocetta, V.; Guarnieri, S.; Savini, V.; Carretto, E.; Bonaventura, G. D., BMC Microbiol., 2015, 15, 109
- Rabin, N.; Zheng, Y.; Opoku-Temeg, C.; Du, Y.; Bonsu, E.; Sintim, H. O., Future Med. Chem., 2015, 7, 493
- Shi, B. B.; Jie, K. C.; Zhou, Y. J.; Zhou, J.; Xia, D. Y.; Huang, F. H., J. Am. Chem. Soc., 2016, 138, 80-83
- Wang, Q.; Cheng, M.; Zhao, Y.; Wu, L.; Jiang, J.; Wang, L.; Pan, Y., Chem. Commun. 2015, 51, 3623-3626
- Wataha, J. C.; Craig, R. G.; Hanks, C. T., Dent. Mater., 1992, 8, 65-71
- Whiteside, M. S.; Kurrasch-Orbaugh, D.; Marona-Lewicka, D.; Nichols, D. E.; Monte, A., Bioorg. Med. Chem., 2002, 10, 3301-3306
- Wiegand, I.; Hilpert, K.; Hancock, R. E. W., Nat. Protoc., 2008, 3, 163
- Xue, M.; Yang, Y.; Chi, X.; Zhang, Z.; Huang, F., Acc. Chem. Res., 2012, 45, 1294-1308
- Xue, Y.; Xiao, H.; Zhang, Y., Int. J. Mol. Sci., 2015, 16, 3626-3655
- Yang, J.; Yu, G.; Xia, D.; Huang, F., Chem. Commun., 2014, 50, 3993-3995
- Yao, Y.; Xue, M.; Chi, X.; Ma, Y.; He, J.; Abliz, Z.; Huang, F., Chem. Commun., 2012, 48, 6505
- Yao, Y.; Chi, X.; Zhou, T.; Huang, F., Chem. Sci., 2014, 5, 2778-2782
- Zhang, H.; Zhao, Y., Chem. Eur. J., 2013, 19, 16862-16879
Claims (15)
1. A compound of formula I:
wherein
R1 is —CR6R7—, wherein R6 and R7 each independently is H, halogen, —COR8, —COOR8, —OCOOR8, —OCON(R8)2, —CN, —NO2, —SR8, —OR8, —N(R8)2, —CON(R8)2, —SO2R8, —SO3H, —S(═O)R8, or (C1-C8)alkyl optionally substituted by one or more groups each independently selected from the group consisting of —COR8, —COOR8, —OCOOR8, —OCON(R8)2, —CN, —NO2, —SR8, —OR8, —N(R8)2, —CON(R8)2, —SO2R8, —SO3H, —S(═O)R8, —N+(R′)3 and —P+(R′)3, wherein R′ each independently is H, (C1-C6)alkyl, phenyl, benzyl, or heterocyclyl, or two R's together with the N atom to which they are attached form a 3-7 membered saturated ring, optionally containing one or more heteroatoms selected from the group consisting of O, S and N and optionally further substituted at the additional N atom;
R2 and R3 each independently is H, halogen, or (C1-C8)alkyl optionally substituted by one or more groups each independently selected from the group consisting of halogen, —COR8, —COOR8, —OCOOR8, —OCON(R8)2, —CN, —NO2, —SR8, —OR8, —N(R8)2, —CON(R8)2, —SO2R8, —SO3H, —S(═O)R8, —N+(R′)3 and —P+(R′)3, wherein R′ each independently is H, (C1-C6)alkyl, phenyl, benzyl, or heterocyclyl, or two R's together with the N atom to which they are attached form a 3-7 membered saturated ring, optionally containing one or more heteroatoms selected from the group consisting of O, S and N and optionally further substituted at the additional N atom;
R4 and R5 each independently is selected from the group consisting of (C1-C10)alkylene, (C2-C10)alkenylene, and (C2-C10)alkynylene, optionally substituted by one or more groups each independently selected from the group consisting of halogen, —COR8, —COOR8, —OCOOR8, —OCON(R8)2, —CN, —NO2, —SR8, —OR8, —N(R8)2, —CON(R8)2, —SO2R8, —SO3H, —S(═O)R8, (C6-C10)aryl, (C1-C4)alkylene-(C6-C10)aryl, heteroaryl, and (C1—C4)alkylene-heteroaryl, and further optionally interrupted by one or more identical or different heteroatoms selected from the group consisting of S, O and N, or by one or more groups each independently selected from the group consisting of —NH—CO—, —CO—NH—, —N(C1-C8alkyl)-, —N(C6-C10aryl)-, (C6-C10)arylenediyl, and heteroarylenediyl;
R8 each independently is H or (C1-C8)alkyl;
Y each independently is (i) a cation derived from a nitrogen-containing group and selected from the group consisting of an ammonium [—N+(R′)3], hydrazinium [—N+(R′)2—N(R′)2], ammoniumoxy [—N+(R′)2→O], iminium [—N+(R′)2═C<], amidinium [—N+(R′)2—C(R′)═NR′], and guanidinium [—N+(R′)2—C(═NR′)—N(R′)2]; (ii) a cation derived from a nitrogen-containing mono- or polycyclic heteroaromatic group and selected from the group consisting of pyrazolium, oxazolium, thiazolium, pyridinium, pyrimidinium, quinolinium, isoquinolinium, 1,2,4-triazinium, 1,3,5-triazinium, and purinium, optionally substituted by one or more groups each independently selected from the group consisting of halogen, (C1-C6)alkyl, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, and —S(═O)H; or (iii) a cation derived from an onium group not containing nitrogen and selected from the group consisting of phosphonium [—P+(R′)3], arsonium [—As+(R′)3], oxonium [—O+(R′)2], sulfonium [—S+(R′)2], selenonium [—Se+(R′)2], telluronium [—Te+(R′)2], stibonium [—Sb+(R′)3], and bismuthonium [—Bi+(R′)3], wherein R′ each independently is H, (C1-C6)alkyl, phenyl, benzyl, or heterocyclyl, or two R's in the ammonium, hydrazinium, ammoniumoxy, iminium, amidinium or guanidinium groups, together with the N atom to which they are attached, form a 3-7 membered saturated ring, optionally containing one or more heteroatoms selected from the group consisting of 0, S and N and optionally further substituted at the additional N atom;
X is a counter anion; and
n is an integer of 5-11,
but excluding the compounds wherein R1 is —CH2—; R2 and R3 are H; and: (i) n is 5; R4 and R5 are —(CH2)2—; and Y is —N+(CH3)3; (ii) n is 5; R4 and R5 are —(CH2)3—; and Y is —P+(C4H9)3; (iii) n is 5; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; (iv) n is 6; R4 and R5 are —(CH2)2—; and Y is —N+(CH3)3; (v) n is 6; R4 and R5 are —(CH2)4—; and Y is —N+(CH3)3; or (vi) n is 6; R4 and R5 are —(CH2)4—; and Y is 1-pyridinium.
2. The compound of claim 1 , wherein:
(i) R1 is —CR6R7—, wherein R6 and R7 each independently is H, halogen, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, or (C1-C8)alkyl optionally substituted by one or more groups each independently selected from the group consisting of —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, —N+(R′)3 or —P+(R′)3, wherein R′ each independently is H, (C1-C4)alkyl, phenyl, or benzyl; or
(ii) R2 and R3 each independently is H, or (C1-C4)alkyl, optionally substituted by one or more groups each independently selected from the group consisting of halogen, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, —N+(R′)3 and —P+(R′)3, wherein R′ each independently is H, (C1-C4)alkyl, phenyl, or benzyl; or
(iii) R4 and R5 each independently is (C2-C10)alkylene, optionally substituted by one or more groups each independently selected from the group consisting of halogen, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, (C6)aryl, (C1-C4)alkylene-(C6)aryl, heteroaryl, and (C1-C4)alkylene-heteroaryl, and further optionally interrupted by one or more identical or different heteroatoms selected from the group consisting of S, O and N, or by one or more groups each independently selected from the group consisting of —NH—CO—, —CO—NH—, —N(C1-C8alkyl)-, —N(C6aryl)-, (C6)arylenediyl, and heteroarylenediyl; or
(iv) R4 and R5 are identical; or
(v) Y each independently is ammonium [—N+(R′)3] or phosphonium [—P+(R′)3], wherein R′ each independently is H, (C1-C6)alkyl, phenyl, benzyl, or heterocyclyl; or
(vi) n is 5, 6, 7 or 8.
3. The compound of claim 2 , wherein:
(i) R1 is —CH2—; or
(ii) R2 and R3 are H; or
(iii) R4 and R5 each independently is (C2-C10)alkylene, optionally interrupted by one or more O atoms; or
(iv) Y each independently is ammonium [—N+(R′)3] or phosphonium [—P+(R′)3], wherein R′ each independently is H, methyl, ethyl, or propyl.
4. The compound of claim 1 , wherein:
R1 is —CR6R7—, wherein R6 and R7 each independently is H, halogen, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, or (C1-C5)alkyl optionally substituted by one or more groups each independently selected from the group consisting of —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, —N+(R′)3 and —P+(R′)3, wherein R′ each independently is H, (C1-C4)alkyl, phenyl, or benzyl;
R2 and R3 each independently is H, or (C1-C4)alkyl, optionally substituted by one or more groups each independently selected from the group consisting of halogen, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, —N+(R′)3 and —P+(R′)3, wherein R′ each independently is H, (C1-C4)alkyl, phenyl, or benzyl;
R4 and R5 each independently is (C2-C10)alkylene, optionally substituted by one or more groups each independently selected from the group consisting of halogen, —COH, —COOH, —OCOOH, —OCONH2, —CN, —NO2, —SH, —OH, —NH2, —CONH2, —SO3H, —SO2H, —S(═O)H, (C6)aryl, (C1-C4)alkylene-(C6)aryl, heteroaryl, and (C1-C4)alkylene-heteroaryl, and further optionally interrupted by one or more identical or different heteroatoms selected from the group consisting of S, O and N, or by one or more groups each independently selected from the group consisting of —NH—CO—, —CO—NH—, —N(C1-C8alkyl)-, —N(C6aryl)-, (C6)arylenediyl, and heteroarylenediyl; and
n is 5, 6, 7 or 8.
5. The compound of claim 4 , wherein R1 is —CH2—; R2 and R3 are H; and R4 and R5 each independently is (C2-C10)alkylene, optionally interrupted by one or more O atoms.
6. The compound of claim 5 , wherein Y is ammonium [—N+(R′)3] or phosphonium [—P+(R′)3], wherein R′ each independently is H, (C1-C6)alkyl, phenyl, benzyl, or heterocyclyl.
7. The compound of claim 6 , wherein Y each independently is ammonium [—N+(R′)3] or phosphonium [—P+(R′)3], wherein R′ each independently is H, methyl, ethyl, or propyl.
8. The compound of claim 7 , wherein n is 5 or 6.
9. The compound of claim 8 , wherein R1 is —CH2—; R2 and R3 are H; X is a counter anion such as Br− or Cl−; and: (i) R4 and R5 are —(CH2)3—, or —(CH2)6—; Y is —N+(CH3)3, —N+(C2H5)3, —P+(CH3)3, or —P+(C2H5)3; and n is 5; or (ii) R4 and R5 are —(CH2)3—;
Y is —N+(CH3)3, or —P+(CH3)3; and n is 6.
10. The compound of claim 1 , wherein said counter anion is Br−, Cl−, F−, I−, PF6 −, BF4 −, OH−, ClO4 −, HSO4 −, CF3COO−, CN−, alkylCOO−, arylCOO−, a pharmaceutically acceptable anion, or a combination thereof.
12. The compound of claim 11 , wherein said counter anion is Br− or Cl−.
13. A composition comprising a compound of the formula I as claimed in claim 1 .
14. The composition of claim 13 , comprising a compound of the formula I, wherein R1 is —CH2—; R2 and R3 are H; X is a counter anion such as Br− or Cl−; and: (i) R4 and R5 are —(CH2)3—, or —(CH2)6—; Y is —N+(CH3)3, —N+(C2H5)3, —P+(CH3)3, or —P+(C2H5)3; and n is 5; or (ii) R4 and R5 are —(CH2)3—; Y is —N+(CH3)3, or —P+(CH3)3; and n is 6.
15. A composition comprising the compound of claim 11 .
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/452,970 US20220119339A1 (en) | 2015-08-10 | 2021-10-29 | Cationic pillararene compounds and compositions |
US18/352,955 US20230365491A1 (en) | 2015-08-10 | 2023-07-14 | Method for inhibiting or disrupting biofilm formation, or reducing biofilm |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL240479 | 2015-08-10 | ||
IL24047915 | 2015-08-10 | ||
PCT/IL2016/050848 WO2017025951A1 (en) | 2015-08-10 | 2016-08-03 | Pillararenes and uses thereof |
US201815751786A | 2018-02-09 | 2018-02-09 | |
US17/452,970 US20220119339A1 (en) | 2015-08-10 | 2021-10-29 | Cationic pillararene compounds and compositions |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/751,786 Division US11161801B2 (en) | 2015-08-10 | 2016-08-03 | Cationic pillararenes and uses thereof |
PCT/IL2016/050848 Division WO2017025951A1 (en) | 2015-08-10 | 2016-08-03 | Pillararenes and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/352,955 Division US20230365491A1 (en) | 2015-08-10 | 2023-07-14 | Method for inhibiting or disrupting biofilm formation, or reducing biofilm |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220119339A1 true US20220119339A1 (en) | 2022-04-21 |
Family
ID=57983675
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/751,786 Active 2037-04-12 US11161801B2 (en) | 2015-08-10 | 2016-08-03 | Cationic pillararenes and uses thereof |
US17/452,970 Abandoned US20220119339A1 (en) | 2015-08-10 | 2021-10-29 | Cationic pillararene compounds and compositions |
US18/352,955 Pending US20230365491A1 (en) | 2015-08-10 | 2023-07-14 | Method for inhibiting or disrupting biofilm formation, or reducing biofilm |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/751,786 Active 2037-04-12 US11161801B2 (en) | 2015-08-10 | 2016-08-03 | Cationic pillararenes and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/352,955 Pending US20230365491A1 (en) | 2015-08-10 | 2023-07-14 | Method for inhibiting or disrupting biofilm formation, or reducing biofilm |
Country Status (3)
Country | Link |
---|---|
US (3) | US11161801B2 (en) |
EP (1) | EP3334706B1 (en) |
WO (1) | WO2017025951A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107098821A (en) * | 2017-06-15 | 2017-08-29 | 西北师范大学 | The quaternized aromatic hydrocarbons of post 5 and synthesis and the application of fluoroscopic examination L tryptophans |
CN108017690B (en) * | 2017-08-17 | 2020-11-24 | 河南师范大学 | Column [5] aromatic artificial transmembrane channel with antibacterial activity and preparation method and application thereof |
EP3502093A1 (en) | 2017-12-20 | 2019-06-26 | Freie Universität Berlin | Zwitterionic pillararene derivative |
CN108640198A (en) * | 2018-05-02 | 2018-10-12 | 南京工业大学 | A method of hexavalent chromium in water body is removed based on absorption method |
CN109054032B (en) * | 2018-06-20 | 2020-11-24 | 西北师范大学 | Preparation and application of supramolecular organic framework and metal complex |
FI20185841A1 (en) * | 2018-10-08 | 2020-04-09 | Aalto Univ Foundation Sr | Macrocyclic compounds and uses thereof |
CN109232614B (en) * | 2018-10-26 | 2021-03-26 | 四川理工学院 | Chiral supramolecules of pillared [5] arene-dicapryl [4] pyrrole, preparation method and application thereof |
CN109851809B (en) * | 2019-03-12 | 2019-09-17 | 华东师范大学 | A kind of column [5] aromatic monomer and its homopolymer and preparation method |
CN110372580B (en) * | 2019-06-20 | 2020-09-01 | 浙江大学 | Separation method of 2-chloropyridine and 3-chloropyridine |
CN110193344B (en) * | 2019-07-03 | 2022-02-11 | 云南民族大学 | Cation column [5] arene modified zeolite adsorption material and preparation method and application thereof |
CN110305333B (en) * | 2019-07-26 | 2022-03-11 | 中山大学 | Column [5] arene polymer microsphere and preparation method and application thereof |
CN111393370B (en) * | 2020-03-30 | 2022-07-19 | 山西大学 | AB monomer based on column [5] arene and imidazole derivative and construction and application of supramolecular polymer network |
FI20205368A1 (en) * | 2020-04-07 | 2021-10-08 | Aalto Univ Foundation Sr | Formulation |
FI20205369A1 (en) * | 2020-04-07 | 2021-10-08 | Helsingin Yliopisto | Combinatory treatment |
CN111517911B (en) * | 2020-05-12 | 2021-06-29 | 浙江大学 | Method for separating m-methyl ethylbenzene from p-methyl ethylbenzene |
CN112011034B (en) * | 2020-08-19 | 2021-09-28 | 盐城海关综合技术服务中心 | Dimethoxy column [ n ] arene knotting conjugated polymer and preparation method and application thereof |
CN113061088B (en) * | 2021-04-09 | 2023-05-02 | 南通大学 | Asymmetric column [5] arene and preparation method and application thereof |
CN114904010B (en) * | 2022-05-06 | 2023-05-23 | 北京师范大学 | Preparation method and application of layered self-assembled siRNA-loaded nanoparticle |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
GB2498356B (en) | 2012-01-11 | 2016-09-07 | Camstent Ltd | Calixarene-derived coatings for implantable medical devices |
CN104447363B (en) | 2014-11-11 | 2016-08-17 | 西北师范大学 | Cation type water-soluble post [5] aromatic hydrocarbons and preparation thereof and as receptor application in detection silver ion |
-
2016
- 2016-08-03 EP EP16834760.7A patent/EP3334706B1/en active Active
- 2016-08-03 WO PCT/IL2016/050848 patent/WO2017025951A1/en unknown
- 2016-08-03 US US15/751,786 patent/US11161801B2/en active Active
-
2021
- 2021-10-29 US US17/452,970 patent/US20220119339A1/en not_active Abandoned
-
2023
- 2023-07-14 US US18/352,955 patent/US20230365491A1/en active Pending
Non-Patent Citations (3)
Title |
---|
Ma et al. Tetrahedron 2013, 69, 4532-4535. (Year: 2013) * |
Ogoshi et al. Chem. Commun., 2012, 48, 3536–3538. (Year: 2012) * |
Yao et al. RSC Adv., 2014, 4, 9039 (Year: 2014) * |
Also Published As
Publication number | Publication date |
---|---|
EP3334706A1 (en) | 2018-06-20 |
EP3334706B1 (en) | 2020-09-30 |
US20200172471A1 (en) | 2020-06-04 |
US20230365491A1 (en) | 2023-11-16 |
EP3334706A4 (en) | 2019-03-13 |
US11161801B2 (en) | 2021-11-02 |
WO2017025951A1 (en) | 2017-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220119339A1 (en) | Cationic pillararene compounds and compositions | |
US11697693B2 (en) | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto | |
KR101955636B1 (en) | A composition comprising an antibiotic and a dispersant or anti-adhesive agent | |
EP2885323B1 (en) | Water soluble nitric oxide-releasing polyglucosamines and uses thereof | |
KR101057609B1 (en) | N, N-dihalogenated amino acids and derivatives | |
Dutta et al. | Counterion-induced modulation in the antimicrobial activity and biocompatibility of amphiphilic hydrogelators: influence of in-situ-synthesized Ag− nanoparticle on the bactericidal property | |
Joseph et al. | Phosphonium pillar [5] arenes as a new class of efficient biofilm inhibitors: importance of charge cooperativity and the pillar platform | |
BRPI0707167A2 (en) | compound, method for inhibiting microbial contamination of a surface, formulation, oligomer or polymer, and surface | |
US8748617B2 (en) | Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same | |
BRPI0920042B1 (en) | USE OF A COMPOUND IN THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF A BACTERIAL BIOFILM INFECTION | |
JP2017218457A (en) | Derivatives of xanthone compounds | |
Fei et al. | Identification of new nitric oxide-donating peptides with dual biofilm eradication and antibacterial activities for intervention of device-related infections | |
WO2020252131A1 (en) | Antibiotic compounds | |
US20210214493A1 (en) | Antimicrobial polycarbonates for multidrug resistant bacteria | |
US11324773B2 (en) | Compounds, compositions and methods for inhibiting a pathogen and/or modifying mucus | |
EP3368517B1 (en) | Compounds, compositions and methods for controlling biofilms | |
BRPI0718014A2 (en) | AMIDE OR SALT COMPOSITE THEREOF, AND BIOPELLIC FORMATION INHIBITOR, BIOPELLIC REMOVER AND BACTERICIDE, EACH ONE USING THE AMIDE OR SALT COMPOUND. | |
CN112313205B (en) | Conjugated oligoelectrolytes as antibacterial agents | |
TW201615694A (en) | Main chain polyamines | |
WO2017186200A1 (en) | Lipophosphonoxins of second generation, and their use | |
ITRM960180A1 (en) | BIS ALCANOIL ESTERS OF CARNITINE WITH ANTIBACTERIAL, ANTI = MYCOTIC AND ANTIPROTOZOARIA ACTIVITY. | |
Aleksandrova et al. | Antibacterial Activity of Various Morphologies of Films Based on Guanidine Derivatives of Pillar [5] arene: Influence of the Nature of One Substitute on Self-assembly | |
CN116284026B (en) | Water-soluble cation molecular cage and synthetic method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |